EUROMEDLAB
2021 MUNICH

24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine
National Congress of the German Society of Clinical Chemistry and Laboratory Medicine
# LIST OF CONTENT

<table>
<thead>
<tr>
<th>Welcome letter</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Committees</td>
<td>11</td>
</tr>
<tr>
<td>Executive Board</td>
<td>11</td>
</tr>
<tr>
<td>Week Agenda</td>
<td>14</td>
</tr>
<tr>
<td>Scientific Programme</td>
<td>19</td>
</tr>
<tr>
<td>Closed Meetings</td>
<td>54</td>
</tr>
<tr>
<td>Speakers and Chairs</td>
<td>56</td>
</tr>
<tr>
<td>Congress Venue</td>
<td>60</td>
</tr>
<tr>
<td>General Information</td>
<td>62</td>
</tr>
<tr>
<td>Registration</td>
<td>67</td>
</tr>
<tr>
<td>Congress Secretariat</td>
<td>71</td>
</tr>
<tr>
<td>Sponsors</td>
<td>72</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>78</td>
</tr>
<tr>
<td>Exhibition map</td>
<td>88</td>
</tr>
<tr>
<td>Exhibitors List</td>
<td>89</td>
</tr>
</tbody>
</table>

---

**DOWNLOAD EUROMEDLAB APP**

Using the EUROMEDLAB App you can display the following:
Scientific programme with speakers' presentations
Posters
General information
Sponsors and exhibitors
Push notifications with the latest news
Breaking news

Sponsored by

![ThermoFisher Scietific Logo](image)
Next-Generation Sequencing Analysis Services

Zymo Research makes next-generation sequencing analyses available to every researcher and industry with our comprehensive portfolio of technologies. With end-to-end and custom solutions available, all NGS services feature state-of-the-art sample processing workflows and cutting-edge bioinformatics at competitive pricing.

Service Available Include:

- Epigenetic Analysis Services
- Gene Expression Analysis Services
- Microbiome Analysis Services
- Epigenetic Aging Services
- Nucleic Acid Purification Services
- Custom Solution Services
- And More!

Learn More at www.zymoresearch.de/pages/services
Multiple testing solutions

Single resource to support all your testing needs

Thermo Fisher Scientific provides a full line of products to support workflow challenges of your laboratory including drug monitoring and screening immunoassays, third-party quality controls for independent validations, and robust LC-MS platforms.

Visit the Thermo Fisher Scientific booth to learn more about the full line of Thermo Scientific™ CEDIA™, DRI™ and QMS™ Assays, the Thermo Scientific Cascadion™ SM Clinical Analyzer, and Thermo Scientific LC-MS medical devices.*

Learn more at thermofisher.com/diagnostics or email us at sales.diagostics.fmt@thermofisher.com

© 2018 Thermo Fisher Scientific Inc. All rights reserved. CEDIA is a trademark of Roche Diagnostics. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

Availability of product in each country depends on local regulatory marketing authorization status.

* For In Vitro Diagnostic Use.
Ladies and Gentlemen:
Distinguished Guests:

It is my pleasure as Lord Mayor to say „Herzlich willkommen!“

I would like to extend a cordial welcome to all of you and I am extremely delighted that this outstanding congress is taking place in the Bavarian State Capital of Munich – a top-ranking location of science and research.

In addition to an excellent scientific and economic infrastructure as well as an efficient road and public transport system, Munich presents a wide range of attractive opportunities to enjoy art, culture and entertainment.

I hope that in the course of your stay you will also have the opportunity to explore the many different attractions in Munich and the surrounding countryside.

I wish you great success for the entire event as well as a pleasant and enjoyable stay.

Yours sincerely,

Dieter Reiter
Lord Mayor
It is my great pleasure to welcome all attendees of the XXIV IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab Congress 2022), jointly hosted by IFCC, EFLM, and the German Society. This is the first major IFCC/EFLM conference held following a long delay caused by the pandemic and an excellent opportunity to bring together laboratory specialists from many national societies both physically and virtually. While this delay was a disappointment for many, we now get to enjoy springtime in Europe with a beautiful backdrop, the city of Munich!

This is a fast-evolving time for the field of clinical chemistry and laboratory medicine, as we face many scientific and technological advancements that allow for a much greater role for our professionals as partners at the centre of healthcare. This timely congress is an excellent opportunity to gather in an international forum to discuss these advancements as well as meet colleagues from across Europe and many other countries around the globe. Without a doubt, the biannual EuroMedLab congress has proven to be one of the leading forums to bring together scientists, laboratory specialists, clinicians, and industry colleagues in the field of clinical chemistry and laboratory medicine. Bringing all of us together in forums like this enables scientific exchange and ensures that our organization and the field of clinical chemistry and laboratory medicine remain at the cutting edge.

During the congress, attendees will get to experience the outstanding scientific program, which features innovative and diverse educational opportunities that incorporate the best of clinical laboratory medicine and in vitro diagnostics, including lectures, symposia, recent advancements in clinical practice and science, poster presentations, and much more. Special emphasis will be placed on technological advancements, as this meeting aims to connect the latest technological breakthroughs in diagnostic laboratory technology with the best minds in laboratory medicine to help attendees learn and implement the latest and greatest in clinical laboratory science, technology, and medicine. In addition to the scientific program, excellent social opportunities have been organized for attendees to enjoy many attractions in Munich.

I hope you all enjoy the excellent scientific and social programs curated by the congress organizing and scientific committees, and I wish you all a productive conference and a pleasant stay in the wonderful city of Munich.

Khosrow Adeli PhD, FCACB, DABCC, FAACC
IFCC President
Dear Colleagues, Dear Friends,

It is our great pleasure and honour to welcome you on behalf of the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), to the 24th EuroMedLab, the IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine organized together by IFCC and EFLM in collaboration with the German Society of Clinical Chemistry and Laboratory Medicine (DGKL).

It is sad and regrettable that this congress comes in such unusual times, when the whole World is fighting against the COVID-19 pandemic. It is also unfortunate that it has been postponed two times. Many of our colleagues are therefore not able to attend the congress due to travel restrictions related to the COVID-19 pandemic.

To those who are fortunate enough to attend the congress in person, on site, we wish an enjoyable experience, good and inspirational congress. We hope you will benefit the scientific program, educational workshops, and exhibition of the IVD industry demonstrating the latest technological advancements and breakthroughs in diagnostic laboratory technology, to help participants to learn and implement the latest and greatest innovations in clinical laboratory science, enjoying also networking and meeting old colleagues and friends and possibly even making some new friends.

To those who will participate in the congress remotely, from a distance, we hope that this conference will also offer a plenty of opportunities to further expand their knowledge and grow. Virtual participation is far from ideal, but given the circumstances and current challenges, this can be acceptable. We trust you will take the most of it. Our sincere wish is that the World is never again faced with what we have experienced during the past two years and that we will get back to our “old normal” soon and certainly before the next EuroMedLab.

Your sincerely,

Prof. Ana-Maria Šimundić
EFLM President (2020-2021)

Prof. Tomris Ozben
EFLM President (2022-2023)
Dear colleagues and friends,

we are glad to be able to welcome you to the EUROMEDLAB 2021 – the XXIV IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine in Munich, Germany as a joint conference by EFLM, IFCC and the national hosting German Society for Clinical Chemistry and Laboratory Medicine (DGKL) (http://www.euromedlab2021munich.org/).

Like with most our private and professional lives during the last two years, the SARS-CoV2 pandemic has also played havoc with all our preparations and efforts to provide you with an in-presence format of this important European congress. You will vividly remember that we had to cancel the start EUROMEDLAB on November 28th 2021 due to a likely shut-down announced for our conference region in Bavaria. Together with a logistically difficult, yet mandatory daily testing regimen for every participant, it would have been impossible to provide the registered participants in Munich with an orderly conference visit and experience. Since then, vaccination programs have further advanced, and vaccines prove their efficiency to protect against serious Covid manifestations every day. As we enter into what is called the endemic stage of SARS-CoV2, restrictions are now increasingly being lifted by health authorities here and abroad as a consequence.

As your organizers, we have been closely and constantly monitoring the situation since and encourage you to attend the EUROMEDLAB and join us in Munich. You will witness an innovative scientific and educational program around the congress and can enjoy the vibrant city of Munich with opportunities for social interactions and networking with colleagues from Europe and beyond. As you can expect from a leading forum for our profession, a broad range of international speakers, key opinion leaders and stakeholders will bring front-edge topics in health care, diagnostic technologies, scientific advances and professional matters to life. Also, you can expect a lively industry exhibition floor featuring the latest products and developments in diagnostic technologies brought to you by the leading manufacturers that look forward to your visit.

We encourage you to visit the EUROMEDLAB website for more information on the program and an early registration (www.euromedlab2021munich.org/registrations/). Undoubtedly, your presence will add to the success of this EUROMEDLAB and we are looking forward to seeing you in Munich and thank you for your continued support and endurance.

With best regards

Prof. Dr. Michael Neumaier
Chair of Organizing committee
Dear colleagues, dear friends,

On behalf of the German Society for Clinical Chemistry and Laboratory Medicine (DGKL), I am pleased to welcome you to EUROMEDLAB 2021 in the International Congress Center of Munich. As we are all aware, the Corona pandemic has forced us to postpone the congress twice for almost a year. Currently, we expect that herd immunity to SARS-CoV 2 will be achieved with the successful vaccination programs in Europe and worldwide and the high infection rates of the milder Omikron variant. When we had to postpone the congress the second time in the fall of 2021, this development was not yet foreseeable. But by now we feel that it is justifiable to offer again a traditional congress in compliance with appropriate measures to avoid infection. With this format, we therefore hope to build on the so successful EUROMEDLAB congresses of the past and enable the very much missed direct scientific exchange and discussion. For those participants who cannot travel to Munich for a variety of reasons, an appropriate digital offering is planned, but in our opinion this can never fully replace the direct experience of a congress.

The organizing committee and the scientific program committee have worked continuously during the pandemic and, in my opinion, have once again put together a wide-ranging, extraordinary scientific program. Special thanks to all the speakers who were able to make the new dates possible despite being postponed twice. The congress program with plenary lectures, symposia including 4 DGKL-symposia, viewpoint sessions, educational workshops, and poster sessions will be complemented by a large exhibition showcasing the latest developments in the diagnostic industry. We are particularly grateful that there was consensus between the organizing committee and the industrial partners to organize an exhibition in the traditional format in compliance with local regulations supplemented by innovative virtual offerings.

I am sure that after a tremendously difficult time this congress in the hospitable city of Munich will provide the forum for fruitful scientific and personal exchange among the participants from all over Europe and the World as we know it from previous EUROMEDLAB congresses.

With my very best regards,

Professor Karl Lackner
Congress President
Optilité®

Optimised and proven special protein analysis

Scan the code to find out more

Contact Us:
www.bindingsite.com
+44 (0) 121 456 9500
info@bindingsite.com
Attend our educational workshops at the EuroMedLab. We are looking forward to welcoming you there.

Workshop 1
Monday, April 11, 2022
14:00 – 15:00 CET, Room 13b

Topic: Providing clinical answers with innovative technology
Chair: Dr Ondrej Valina
Sysmex Europe GmbH
Speakers:
PD Dr Mathias Zimmermann
virtual talk, DRK Kliniken, Berlin, Germany;
Prof. Johan Elf
University Uppsala, Sweden

Workshop 2
Monday, April 11, 2022
15:30 – 16:30 CET, Room 13a

Topic: Let your lab work flow: Striving for operational excellence
Chair: Maros Heidinger
Sysmex Europe GmbH
Speakers:
Rexhina Cipi
Sysmex Europe GmbH;
Johanna Engelage
Sysmex Europe GmbH;
Tanja Tornow
Sysmex Europe GmbH

Workshop 3
Tuesday, April 12, 2022
14:00 – 15:00 CET, Room 13b

Topic: Towards a smarter lab with digitally enhanced solutions
Chair: Theo Hofman
Sysmex Europe GmbH
Speakers:
Dr Jean-Marc Giannoli
Biogroup Laboratories, Neuville-sur-Saône, France;
Dr Patrick Cohen
virtual talk, Geneva University Hospital, Switzerland;
Koray Yurdakul
Sysmex Turkey

We will host further exciting sessions in our live presentation area on our booth!
Go to this page for a schedule of our live presentation area sessions and details on our upcoming workshops:

www.sysmex-europe.com/EML2021
COMMITTEES

CONGRESS ORGANISING COMMITTEE
Michael Neumaier, Chair
Karl Lackner, Congress President
Philippe Gillery, SPC Chair
Maria Montserrat Blanes Gonzalez
Stefano Montalbetti
Rolf Hinzmann
Tomris Ozben
Abir Alhelou
Tomás Zima

SCIENTIFIC PROGRAMME COMMITTEE
Philippe Gillery, Chair
Christa Cobbaert
Eric Kilpatrick
Karl Lackner, Congress President
Sverre Sandberg
Saara Wittfooth

INTERNATIONAL SCIENTIFIC ADVISORY BOARD
Anyla Bulo Kasneci (Albania)
Andrea Griesmacher (Austria)
Joris Delanghe (Belgium)
Radivoj Jadric (Bosnia Herzegovina)
Dobrin A. Svinarov (Bulgaria)
Jasna Lenicek Krleza (Croatia)
Spyroula Christou (Cyprus)
Richard Pickner (Czech Republic)
Kalle Kisand (Estonia)
Kari Pulkkki (Finland)
Sylvain Lehmann (France)
Jürgen Ruland (Germany)
Costas Makris (Greece)
Éva Ajzner (Hungary)
Leifur Franzson (Iceland)
Marielle Kaplan (Israel)
Giuseppe Lippi (Italy)
Valdete Topciu Shufta (Kosovo)
Dalius Vitkus (Lithuania)
Jasna Bogdanska (Macedonia)
Robert de Jonge (Netherlands)
Jens Petter Berg (Norway)
Katarzyna Fischer (Poland)
João Faro Viana (Portugal)
Cristina Mambet (Romania)
Andrei Ivanov (Russia)
Snezana Jovicic (Serbia)
Hedviga Pivovarniková (Slovak Republic)
Blaz Krhin (Slovenia)
Antonio Buño (Spain)
Mats Ohlson (Sweden)
Michel F. Rossier (Switzerland)
Dogan Yucel (Turkey)
Dimitris Grammatopoulos (UK)

EXECUTIVE BOARDS

IFCC EXECUTIVE BOARD
Khosrow Adeli, President
David Kinniburgh, Secretary
Alexander Haliassos, Treasurer
Joseph Passarelli, Corporate Representative
Adekunle B Okesina, African Federation of Clinical Chemistry (AFCC)
Abderrazzek Hedhili, Arab Federation of Clinical Biology (AFCB)
Endang Hoyaranda, Asia-Pacific Federation for Clinical Biochemistry and Laboratory Medicine (APFCB)
Tomris Ozben, European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Ana María Lena Rodríguez, Latin-American Confederation of Clinical Biochemistry (COLABIOCLI)
Stephen Hill, North American Federation of Clinical Chemistry and Laboratory Medicine (NAFCC)

EFLM EXECUTIVE BOARD
Tomris Ozben, President
Ana-Maria Simundic, Past President
Mario Plebani, President-Elect
Snezana Jovicic, Secretary
Klaus P. Kohse, Treasurer
Pilar Fernandez-Calle, Member-at-Large
Dalius Viktus, Member-at-Large

DGKL EXECUTIVE BOARD
Harald Renz, President
Mariam Klouche, Vice-president
Matthias Nauck, Past President
Matthias F. Bauer, Treasurer
Katrin Borucki, Secretary
Ralf Lichtinghagen, Further Member
Thomas Streichert, Further Member
### IFCC ROCHE TRAVEL SCHOLARSHIP

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ochieng Wycliff</td>
<td>Kenya</td>
</tr>
<tr>
<td>Elizabeth Chinbayo</td>
<td>Malawi</td>
</tr>
<tr>
<td>Mohammed I. K. Alhaddad</td>
<td>Palestine</td>
</tr>
</tbody>
</table>

### EFLM BURSARIES FOR YOUNG SCIENTISTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jakob Adler</td>
<td>Germany</td>
</tr>
<tr>
<td>Erhan Canbay</td>
<td>Turkey</td>
</tr>
<tr>
<td>Marian Caro Miro’</td>
<td>Spain</td>
</tr>
<tr>
<td>Blanca Fabre Estremera</td>
<td>Spain</td>
</tr>
<tr>
<td>Marie Lenski</td>
<td>France</td>
</tr>
<tr>
<td>Ivona Mitu</td>
<td>Romania</td>
</tr>
<tr>
<td>Agnieszka Ochocińska</td>
<td>Poland</td>
</tr>
<tr>
<td>Emmi Rotgers</td>
<td>Finland</td>
</tr>
<tr>
<td>Mariana Serres Gomez</td>
<td>Spain</td>
</tr>
<tr>
<td>Tirsa Van Duijl</td>
<td>Netherlands</td>
</tr>
</tbody>
</table>

### EFLM BURSARIES IN MEMORY OF VIC BLATON - RESERVED TO SELECTED EFLM COUNTRIES

<table>
<thead>
<tr>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nataliia Kozopas</td>
<td>Ukraine</td>
</tr>
<tr>
<td>Neda Milinkovic</td>
<td>Serbia</td>
</tr>
<tr>
<td>Elena Petrushevska Stanojevska</td>
<td>North Macedonia</td>
</tr>
<tr>
<td>Tamar Ramishvili</td>
<td>Georgia</td>
</tr>
<tr>
<td>Elira Tashi</td>
<td>Albania</td>
</tr>
</tbody>
</table>

### EFLM AWARDS

- **EFLM Award for Scientific Achievements in Laboratory Medicine**
  
  *Sponsored by Roche*

- **EFLM Award for Achievements in Advancing Laboratory Medicine**
  
  *Sponsored by Roche*

- **EFLM Award for Excellence in Outcomes Research in Laboratory Medicine**
  
  *Sponsored by Abbott Diagnostics*

- **EFLM Award for Excellence in Performance Specifications Research**
  
  *Sponsored by Abbott Diagnostics*

- **EFLM Cardiac Marker Award**
  
  *Sponsored by HyTest*
MAGLUMI® X3

Save Your Space without Compromise
* Compatible with Small and Medium-sized Hospitals and Labs

All Balanced and Strong

Small but strong
The throughput is up to 200 tests/hour, and the throughput per unit area is 294 T/h/m². Compatible with all MAGLUMI® reagents with perfect compatibility (166 parameters).

Convenient and efficient
No-pause loading/unloading of reagents/samples/reaction cups without waiting or interrupting tests. Intuitive indicator lights make no need to check reagents and consumables frequently.

Low failure rate and accurate result
The single reaction cup can avoid light pollution and increase cuvette utilization, its integrated packaging can avoid the stuck of the cuvette, cuvette blockage and scratches.

Cost-efficient and intelligent
TEFLON-coated pipetting needle is equipped with independent washing unit to avoid carry-over (Small workload analyzer have higher consumable costs when using disposable Tips).

Excellent performance
The comprehensive advanced design of MAGLUMI® X3 ensures excellent performance, such as the latest intelligent washing technology and bidirectional temperature control measurement.

www.snibe.com  |  sales@snibe.com
### Sunday 10 April

- **ROOM 14**
  - 17.00-20.00: OPENING CEREMONY
  - Welcome reception

### Monday 11 April

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Room 1</th>
<th>Room 5</th>
<th>Room 13a</th>
<th>Room 13b</th>
<th>Room 14a</th>
<th>Room 14c</th>
<th>Exhibition Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>10.00</td>
<td><strong>PL 1</strong></td>
<td>Fine tuning of innate immunity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>10.30</td>
<td><strong>SYM 1</strong></td>
<td>Acute Kidney Injury biomarkers: from lab to bedside</td>
<td><strong>SYM 2</strong></td>
<td>Chronic myeloproliferative neoplasms</td>
<td><strong>SYM 3</strong></td>
<td>Performance Specifications in Laboratory Medicine - from different models to practical use</td>
<td><strong>SYM 4</strong></td>
</tr>
<tr>
<td>12.30</td>
<td>14.00</td>
<td>POSTER SESSION</td>
<td>LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td>15.00</td>
<td><strong>EDUW 1</strong></td>
<td>Siemens</td>
<td><strong>EDUW 3</strong></td>
<td>Abbott</td>
<td><strong>EDUW 4</strong></td>
<td>Sysmex</td>
<td><strong>EDUW 5</strong></td>
</tr>
<tr>
<td>15.30</td>
<td>16.30</td>
<td><strong>VIEWPOINT</strong></td>
<td>Is eGFR the gold standard for evaluating renal dysfunction?</td>
<td><strong>EDUW 6</strong></td>
<td>Mindray</td>
<td><strong>EDUW 7</strong></td>
<td>Sysmex</td>
<td><strong>EDUW 8</strong></td>
</tr>
<tr>
<td>17.00</td>
<td>18.00</td>
<td><strong>VIEWPOINT</strong></td>
<td>Quantitative mass spectrometry vs immunoassays of clinically relevant peptides and proteins</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**LEGEND**
- PL: Plenary Lecture
- SYM: Congress Symposium
- EDUW: Educational Workshop
- HYBRID SESSIONS: 📚

**Sunday 10 April**
- ROOM 14
  - 17.00-20.00: OPENING CEREMONY
  - Welcome reception

**Monday 11 April**
- ROOM 1
- ROOM 5
- ROOM 13a
- ROOM 13b
- ROOM 14a
- ROOM 14c
- Exhibition Hall
**Tuesday 12 April**

<table>
<thead>
<tr>
<th>Time</th>
<th>Room</th>
<th>Room 1</th>
<th>Room 5</th>
<th>Room 13a</th>
<th>Room 13b</th>
<th>Room 14a</th>
<th>Room 14c</th>
<th>Exhibition Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00-10.00</td>
<td>PL 2</td>
<td>Biomarkers for cardiovascular risk stratification</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-12.30</td>
<td>SYM 7</td>
<td>Implementation of Liquid Biopsy</td>
<td>SYM 8</td>
<td>New approaches for determining reference intervals across all ages</td>
<td>SYM 9</td>
<td>New insights in amyloidosis</td>
<td>SYM 10</td>
<td>How to make EQA fit for purpose?</td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>POSTER SESSION</td>
<td>LUNCH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td>EDUW 15</td>
<td>Ortho</td>
<td>EDUW 17</td>
<td>Abbott</td>
<td>EDUW 18</td>
<td>Symex</td>
<td>EDUW 19</td>
<td>Roche</td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>VIEWPOINT</td>
<td>Biomarkers of alcohol abuse in clinical and forensic use – strengths and limitations</td>
<td>EDUW 20</td>
<td>Mindray</td>
<td>EDUW 21</td>
<td>GMT Science</td>
<td>EDUW 22</td>
<td>Sebia</td>
</tr>
<tr>
<td>17.00-18.00</td>
<td>VIEWPOINT</td>
<td>Which future for HbA1c as biomarker of diabetes monitoring?</td>
<td>EDUW 26</td>
<td>Siemens</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Week Agenda

### Wednesday 13 April

<table>
<thead>
<tr>
<th>Room</th>
<th>Room 1</th>
<th>Room 5</th>
<th>Room 13a</th>
<th>Room 13b</th>
<th>Room 14a</th>
<th>Room 14c</th>
<th>Exhibition Hall</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>PL 3 Integrative Diagnostics as the Key Driver for Intelligent Systems in Medicine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-17.30</td>
<td>Exhibition open</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00-10.30</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30-12.30</td>
<td>SYM 15 High-sensitivity troponins and beyond</td>
<td>SYM 14 Advances in IQC tools and techniques</td>
<td>SYM 13 Porphyrias – integration of laboratory medicine and clinical care (A symposium in memorial of the 140 years anniversary of the birth of Hans Fischer)</td>
<td>SYM 16 Health platforms of the future and clinical relevance of interoperability</td>
<td>SYM 17 New trends in standardization</td>
<td>DGKL Personalised medicine in allergy diagnostics</td>
<td></td>
</tr>
<tr>
<td>12.30-14.00</td>
<td>POSTER SESSION</td>
<td>Lunch</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.00-15.00</td>
<td>EDUW 29 Ortho</td>
<td>EDUW 31 Abbott</td>
<td>EDUW 32 Siemens</td>
<td>EDUW 33 Roche</td>
<td>SYM 18 (14.00 - 16.00) Consequences of IVDR Regulations on Laboratory Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.30-16.30</td>
<td>VIEWPOINT Regulating direct-to-consumer testing 2.0: Protecting the consumer</td>
<td></td>
<td>EDUW 35 BD</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17.00-18.00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## WEEK AGENDA

### Thursday 14 April

<table>
<thead>
<tr>
<th>ROOM</th>
<th>ROOM 1</th>
<th>ROOM 5</th>
<th>ROOM 13a</th>
<th>ROOM 13b</th>
<th>ROOM 14a</th>
<th>ROOM 14c</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>PL 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>Towards next generation diagnostics by X-omics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.00</td>
<td>BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.30</td>
<td>SYM 23</td>
<td>SYM 20</td>
<td>SYM 21</td>
<td>SYM 22</td>
<td>SYM 19</td>
<td>DGKL</td>
</tr>
<tr>
<td>12.30</td>
<td>How does Point of Care Testing change the clinical pathways?</td>
<td>Autoimmune Encephalitis</td>
<td>Urinalysis: a new look at old tests</td>
<td>Young Scientist Session</td>
<td>New diagnostic approaches in Laboratory Medicine</td>
<td>Emerging infectious diseases – impact of laboratory diagnosis</td>
</tr>
<tr>
<td></td>
<td>Closing Ceremony</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

WEEK AGENDA
We pioneer breakthroughs in healthcare.
For everyone. Everywhere.
siemens-healthineers.com/euromedlab

Intelligent, integrated IVD solutions that deliver innovative workflow efficiencies, clinical insights, and digital applications.

Learn more at EUROMEDLAB Munich
Booth #83, Hall C1
April 11 – 13
Welcome addresses
Euromedlab Munich 2021 President, K. Lackner
Euromedlab Munich 2021 Chair, M. Neumaier
IFCC President, K. Adeli
EFLM President, T. Ozben
DGKL President, H. Renz

Announcement of EFLM Awards
EFLM President, T. Ozben

OPENING LECTURE
Chair: M. Neumaier

Where, when, and how?
The Quest for Extraterrestrial Life
W. Duschl (Germany)

Welcome Cocktail

Prof. Dr. Wolfgang J. Duschl

• 1958 born in Munich, Germany

• 1985 PhD from the University of Munich (LMU and Max Planck Institute for Astrophysics)

• Worked at the Universities of Heidelberg (Germany), Cambridge (UK), and Arizona (Tucson, USA), and the Max Planck Institutes of Astrophysics (Garching, Germany) and Radio Astronomy (Bonn, Germany)

• Current positions: Director and Full Professor of Astrophysics at the Christiana Albertina University (CAU, Kiel, Germany); Affiliated Astronomer at Steward Observatory (Tucson, AZ, USA); Prof.h.c. at Irkutsk State University (Russia); Chairman of the Academic Senate of the CAU; Chairman-elect of the Board of Directors of the International Journal “Astronomy & Astrophysics”

• Main research fields: Atmospheres of exoplanets; evolution of supermassive black holes in galactic centers
9:00-10:00  **PLENARY LECTURE**  
*Chair: P. Gillery (France)*

Fine tuning of innate immunity  
*T. Chavakis (Germany)*

10:00-10:30  Break

---

**Triantafyllos Chavakis**

is director of the Institute for Clinical Chemistry and Laboratory Medicine of the University Clinic Dresden since 2017. He was a principal investigator and head of the Inflammation Biology Section of the Experimental Immunology Branch, National Cancer Institute, NIH, Bethesda MD from 2005-2010. His research focuses on Innate Immunity and Metabolic Inflammation. Specifically, his lab aims at identifying mechanisms that are involved in the regulation of inflammation in the context of metabolic-inflammatory pathologies (obesity-related insulin resistance and NAFLD), inflammatory bone loss and cancer. A further focus is on innate immune cell generation (myelopoiesis) and activation in the context of trained innate immunity (a form of innate immune memory).
10:30-12:30  ROOM 1

SYMPOSIUM 1
Acute Kidney Injury biomarkers: from lab to bedside
Chairs: C. Ronco (Italy), F. Alcantara (Brazil)

The continuum of AKI and the utility of biomarkers
C. Ronco (Italy)

New Biomarkers in AKI: application in clinical routine
L. Forni (UK)

Prevention/protection of the kidney guided by biomarkers
M. Ostermann (UK)

Urinary kidney injury biomarkers determined by LC-MRM-MS in health and disease
T. van Duijl (The Netherland)

The role of the laboratory in the early detection of acute kidney injury in hospitalised patients
R. Galván (Spain)

10:30-12:30  ROOM 5

SYMPOSIUM 2
Chronic myeloproliferative neoplasms
Chairs: D. Coriu (Romania), S.N. Constantinescu (Belgium)

Diagnostic algorithm in myeloproliferative neoplasms
D. Coriu (Romania)

Inhibiting pathologic signaling induced by driver and epigenetic mutations in myeloproliferative neoplasms: monitoring treatment by next generation sequencing
S.N. Constantinescu (Belgium)

Challenges of using next-generation sequencing technologies in the clinical management of myeloproliferative neoplasms
C. Mambet (Romania)

ALNeT: a new deep learning model for the diagnosis of acute leukaemia lineage using peripheral blood cell images
J. Rodellar (Spain)
10:30-12:30  ROOM 13a

SYMPOSIUM 3
Performance Specifications in Laboratory Medicine – from different models to practical use
Chairs: S. Sandberg (Norway), A. R. Horvath (Australia)

Analytical performance specifications: From models to practical use
S. Sandberg (Norway)

Outcome-based models – a link between clinical and analytical performance
A.R. Horvath (Australia)

A practical way of calculating measurement uncertainty in laboratory medicine and compare it to APS
A. Coskun (Turkey)

Analytical Performance Specifications Derived from Uncertainty Budgets Based on Clinical Decision Limits
E.S. Rotgers (Finland)

10:30-12:30  ROOM 13b

SYMPOSIUM 4
Clinical Use Cases for Integrated diagnostics for Laboratory Medicine and Radiology
Chairs: M. Fuchsjäger (Austria), M. Neumaier (Germany)

EIBIR, a support platform for research funding in future integrative diagnostics between imaging and the laboratory
K. Krischak (Austria)

Personalized Diagnostics in detection of recurrence of metastatic colorectal cancer
S. Schönberg (Germany), V. Haselmann (Germany)

Prediction of prognosis based on laboratory data and chest CT
S. Cappabianca (Italy)

Integrative diagnostics to investigate tissue damage dynamics
M. Frölich (Germany), C. Gerhards (Germany)
10:30-12:30  ROOM 14a

SYMPOSIUM 5
COVID-19: biology, clinics, laboratory diagnostics and biosafety issues
Chairs: G. Lippi (Italy), K. Adeli (Canada)

Biology and clinics of COVID-19
G. Lippi (Italy)

Molecular and serological testing of COVID-19
K. Adeli (Canada)

Laboratory responsiveness to COVID-19: results of an IFCC survey
T.P. Loh (Singapore)

Clinical laboratory testing in a pandemic: what we have learned from the COVID-19 experience
D. Koch (USA)

10:30-12:30  ROOM 14c

DGKL SYMPOSIUM
Metabolomics via NMR spectroscopy
Chairs: M. Nauck (Germany), U. Günther (Germany)

Lipoprotein diagnostics via NMR. From research to clinical application
M. Nauck (Germany)

Blood Lipo- and Glycoproteins in COVID-19 Patients
U. Günther (Germany)

NMR Biomarker Research: Targeted and untargeted approach
A. Petersmann (Germany)

Association of triacylglycerol-glucose index with low-density lipoprotein particle number and size measured by proton nuclear magnetic resonance spectroscopy
O. Racz (Slovakia)

Serum Metabolome Analysis of Iron Deficiency Anemia Patients Using Nuclear Magnetic Resonance (Quantitative Approach)
A.Z. Gul (Turkey)

12:30-14:00  HALL C1

POSTER SESSION
14:00-16:00 ROOM 14c

SYMPOSIUM 6
Artificial intelligence, data science and laboratory medicine: crossed destinies
Chairs: D. Gruson (France), M. Cowie (UK)

The AI data wave, seizing opportunities
M. Cowie (UK)

How to dive into large scale dataset?
B. Macq (Belgium)

What are the keys for Europe as a space for data and AI?
Y. Tolias (Belgium)

Round Table
M. Cowie (UK), B. Macq (Belgium), Y. Tolias (Belgium)

15:30-16:30 ROOM 1

VIEWPOINT 1
Is eGFR the gold standard for evaluating renal dysfunction?
Chair: K. Makris (Greece)

Measuring GFR–tohubohu
E. Schaeffner (Germany)

Estimating eGFR: no blind trust
C. Mariat (France)

17:00-18:00 ROOM 1

VIEWPOINT 2
Quantitative mass spectrometry vs immunoassays of clinically relevant peptides and proteins
Chair: C. Cobbaert (Netherlands)

Can quantitative mass spectrometry replace immunoassays for blood proteins? The only question is when?
C. Borchers (Canada)

Quantitative mass spectrometry cannot replace immunosays for blood proteins
S. Lehmann (France)
SESSION
Containment of a viral pandemic: is diagnostic performance rate-limiting?
Chairs: M. Kittel (Germany), M. Neumaier (Germany)

Lessons from the CoVLAB initiative: diagnostic performance vs scalability
M. Kittel (Germany)

Pebble: filling-in the gap of point-of-care molecular testing
D. Kourougkiaouri (Greece), S. Katsaros (Greece)

Rational clinical use of POCT methods for molecular detection of infectious agents
P. Luppa (Germany)
CoVLAB is our innovative contribution in the fight against the SARS-CoV-2 pandemic. For almost two years this mobile corona test station has been on tour in the federal state Baden-Württemberg – demand-actuated, fast and flexible on site. This was made possible by a mobile biosafety lab with high-end equipment for molecular biological virus detection. The project was specifically developed for the detection of SARS-CoV-2 infections.

Please take the opportunity to take part in a guided tour and discussions with our medical team.

You will find us at EuromedLab next to the main entrance from April 11th until April 14th, 2022.
COMPANIES’ EDUCATIONAL WORKSHOPS MONDAY, 11 APRIL

14.00-15.00 ROOM 1
EDUW 1 – SIEMENS HEALTHINEERS
Title: High Sensitivity cardiac Troponin I: Central lab or POC, the choice is yours
Chair: Alessandro Ortisi – Siemens Healthineers, Associate Director Global Clinical Marketing

Speakers:
Johannes Neumann, MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
Evaluation of patients with suspected myocardial infarction
Nils A. Sörensen MD – Department of Cardiology, University Heart and Vascular Center Hamburg, German Center for Cardiovascular Research (DZHK), Hamburg, Germany
High-sensitivity point-of-care troponin testing

Learning Objectives:
• Understand diagnostic steps required in patients with suspected myocardial infarction
• Learn about diagnostic algorithms using high-sensitivity troponin assays
• Learn about novel diagnostic strategies using point-of-care assays

14.00-15.00 ROOM 13a
EDUW 3 – ABBOTT
Title: Novel Blood Tests for Game-Changing Detection and Treatment of Traumatic Brain Injury
Chair: Dr. Alex Carterson – DVP Medical, Clinical and Scientific Affairs, Abbott

Speakers:
Peter Biberthaler, MD – Chair, Department of Trauma Surgery, Technical University Munich
Diagnostic Dilemma of mild Traumatic Brain Injury
Beth McQuiston, MD – Senior Medical Director, Abbott
Traumatic Brain Injury: State of the Art Management

Learning objectives:
• Recognize the crucial unmet need for improved brain health assessment
• Appreciate the objective value of GFAP (Glial Fibrillary Acidic Protein) and UCH-L1 (plasma ubiquitin C-terminal hydrolase-L1) as new game-changing tests that help clinicians evaluate the brain and optimize care pathways for traumatic brain injury
• Identify collaborative opportunities to achieve measurably better outcomes related to TBI (Traumatic Brain Injury) for patients, payors clinicians and health systems.

14.00-15.00 ROOM 13b
EDUW 4 – SYSMEX
Title: Providing clinical answers with innovative technology
Chair: Dr. Ondrej Valina – Sysmex Europe GmbH

Speakers:
PD Dr. Mathias Zimmermann, DRK Kliniken Berlin, Germany
Prof. Johan Elf, University Uppsala, Sweden

Learning objectives:
Sysmex as an IVD manufacturer is aware about diagnostic challenges of clinicians in everyday routine. This workshop will review the current practice in infection diagnostics (performance and availability of biomarkers and lab tests) and present products and technologies from haematology and point-of care that can close gaps in diagnostic information. The learning objective is to create awareness for already available and future innovative products with the aim to improve healthcare.
14.00-15.00  ROOM 14a
EDUW 5 – ROCHE
Title: Pandemic Preparedness
Chair: Dr. Christian Simon, Roche Diagnostics

Speakers:
P.Dr.med. Andreas Wieser, Global Health & Infectious Diseases at the Medical Center of the University of Munich

Fighting Emerging Pathogens – the COVID Pandemic response in Germany
Prof.Dr.med. Stefan Holdenrieder, Director of the Institute of Laboratory Medicine, German Heart Center of the Technical University Munich

Diagnostic follow-up in a post vaccine setting
Learning objectives:
We're now almost two years on since the COVID-19 pandemic first hit and yet great uncertainty remains. Whilst there has been huge progress in terms of vaccine development and administration, less than a third of the world's population has received one or more doses of a SARS-CoV-2 vaccine, and there is great variation between countries. As new strains of the virus develop, we must aim for complete vaccine coverage, else we leave ourselves collectively exposed. And as the virus adapts, so must our communal response. To date we have led with social distancing measures and lockdown legislations, but reliable antibody testing enables widespread mass screening that - in combination with local and national policies – can modify and optimize restriction strategies. The information collected can also help scientists assess the exposure of different populations and levels of disease burden so that they can begin to predict its spread. The resulting insights can be used to inform strategies aiming to further contain and counter the virus, optimize governmental responses and ready health services so they are better able to cater to the needs of the people they serve.

15.30-16.30  ROOM 5
EDUW 6 – MINDRAY
Title: The pre-classification of digitized images from peripheral blood
Chairs: Giuseppe D’Onofrio – Università Cattolica del Sacro Cuore, Rome, Italy
Francesca Mancini – Policlinico Umberto I, Rome, Italy

Speaker:
Gina Zini – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

The pre-classification of digitized images from peripheral blood
Learning objective:
Morphological evaluation of peripheral blood (PB) and bone marrow (BM) blood cells through optical microscopic (OM) examination remains a cornerstone in hematological diagnosis. The development of digitized cell images technology and the current availability of systems capable of pre-classifying digitized blood cell images from PB smears offers practical possibilities of clinical applications and new opportunities in the hematology laboratory practice. In this workshop comparison between morphology under OM and digitized morphology pre-classification on PB smears from onco-hematological patients will be presented.
15.30-16.30 ROOM 13a

EDUW 7 – SYSMEX
Title: Let your lab work flow. Striving for operational excellence.
Chair: Maros Heidinger – Sysmex Europe GmbH

Speakers:
Rexhina Cipi, Germany – Sysmex Europe GmbH
Johanna Engelage, Germany – Sysmex Europe GmbH
Tanja Tornow, Germany – Sysmex Europe GmbH

Learning objectives:
When designing a specific work area in the laboratory, one of the challenges is to consider the surrounding processes while targeting their significant improvement, and the selection of a specific analyser configuration best possible supporting the key improvement points and KPIs defined by the laboratory. For decades, the Lean methodology has offered the respective tools and procedures for identifying and eliminating waste in processes. This workshop demonstrates the application of the Lean methodology to specific work areas with the aim to identify optimisation potential by eliminating waste and present solutions specifically addressing the identified optimisation potential.

15.30-16.30 ROOM 13b

EDUW 8 – WATERS
Title: The role of LC-MS in a clinical laboratory

Speakers:
Benjamin Dugas, Senior Global Marketing Manager Clinical Diagnostics
Godo Bosch, Director Strategic Development Clinical Markets, EMEA
Katharina Kern, Lead Mass Spectrometry Group, R&D, RECIPE GmbH, Munich

Learning objectives:
While Immunoassays play a central role in Clinical Laboratories some needs have required the search for new technologies. We will discuss what Liquid Chromatography with Mass Spectrometry (LC-MS) is, what it brings to the laboratory and how it complements Immunoassays. Examples in routine work such as Endocrinology and Therapeutic Drug Monitoring assays will support the discussion. A short look at future possibilities will also be exposed with SARS CoV2 virus measurements.

15.30-16.30 ROOM 14a

EDUW 9 – SNIBE
Title: New insights in immunoassays
Chair: Prof. Mario Plebani

Speakers:
Prof. Mario Plebani - Department of Laboratory Medicine, University Hospital of Padova, Italy
SARS-CoV- 2 antibodies testing: why, when and how?
Prof. János Kappelmayer - Department of Laboratory Medicine, University of Debrecen, Hungary
Experience with AMH and Tacrolimus measurements on the MAGLUMI 800 analyzer

Learning objectives:
The main learning objective of the workshop is to offer an update in the field of immunoassays. Immunoassays still play a central role in laboratory medicine, but some issues require further efforts:
• Harmonization and standardization
• Immunoassays versus mass spectrometry
• Biological function versus mass concentration: the case of SARS-CoV-2 neutralizing antibodies
The perfect match for screening hemoglobin disorders in newborns

- High throughput instrument
- Full traceability
- High autonomy
- Excellent Resolution
- Automatic Reagent Control

Come & visit Sebia’s booth #121 at the IFCC EuroMedLab Munich 2021
SCIENTIFIC PROGRAMME TUESDAY, 12 APRIL

9:00-10:00  **PLENARY LECTURE**  
*Chair: K. Lackner (Germany)*

Biomarkers for cardiovascular risk stratification  
*S. Blankenberg (Germany)*

10:00-10:30  Break

---

**Stefan Blankenberg**

1989 - 1996  Studies of Medicine at Johannes Gutenberg-University, Mainz  
Johann Wolfgang Goethe-University, Frankfurt and  
Mount Sinai Medical School, New York, USA

1996  State Examination, Medical Doctor

1996 - 2002  Wissenschaftlicher Assistent (resident and fellow) at the Department of Medicine II, Johannes Gutenberg-University Mainz

2002 - 2003  INSERM Scholarship for post-doctoral training in “Molecular Genetics and Genetic Epidemiology” at INSERM U525, Faculté de Médecine Pitié-Salpêtrière Paris, France

2003 - 2005  Wissenschaftlicher Assistent (resident and fellow) at the Department of Medicine II, Johannes Gutenberg-University Mainz

2004  PhD thesis (Habilitation) at the Department of Medicine II, Johannes Gutenberg-University Mainz

2005 - 2011  Senior physician at the Department of Medicine II, Johannes Gutenberg-University Mainz

2005 - 2011  Full Professor of Medicine and Faculty Member of the Johannes Gutenberg-University Mainz

2007 - 2011  Leading senior physician and deputy director of the Department of Medicine II, Johannes Gutenberg University of Mainz

2008 - 2011  Speaker of the “Schwerpunkt Vaskuläre Prävention” (Interdisciplinary task force “Vascular prevention”) of the Johannes Gutenberg University, Mainz

2011 - present  Director of the Clinic for Cardiology, University Heart Center, Hamburg

2011 - present  Board of Directors, German Center for Cardiovascular Research (DZHK)

2011 - 2019  Speaker Cardiovascular Research Center Hamburg, University Medical Center Hamburg Eppendorf, Germany

2012 - 2018  Speaker of the German Heart Research Center (DZHK) Partner Site Hamburg

2013 - 2021  (April) Board of Directors, German Society of Cardiology

2018 - present  Medical Director of the University Heart & Vascular Center Hamburg
10:30-12:30 ROOM 1

**SYMPOSIUM 7**

Implementation of Liquid Biopsy

*Chairs: M. Neumaier (Germany), V. Haselmann (Germany)*

Liquid Biopsy/cell free DNA: talk of the town, but where is the action?  
*R. van Schaik (Netherlands)*

Cancer Epigenetic Biomarkers in Liquid Biopsy  
*S.A. Joosse (Germany)*

The importance of Integrative molecular analysis in Liquid biopsies  
*E. Lianidou (Greece)*

HTA of clinical decision-making of circulating nucleic acids in cancer patients  
*M. IJzerman (Australia)*

---

10:30-12:30 ROOM 5

**SYMPOSIUM 8**

New approaches for determining reference intervals across all ages  

*Chairs: Y. Ozarda (Turkey), T. Streichert (Germany)*

Comparison of different approaches for deriving reference intervals  
*Y. Ozarda (Turkey)*

Age related RIs: Methods for continuous RIs and possible applications  
*T. Streichert (Germany)*

A new computer-intensive approach for the indirect derivation of reference intervals  
*K. Ichihara (Japan)*

Pediatric Reference Intervals for Trace Elements in the CALIPER cohort of healthy children and adolescents using ICP-MS/MS and HR-MS Technology  
*M. K. Bohn (Canada)*

NUMBER-2: The automation and extension to routine haematology of the Dutch indirect data-mining approach to establish population-specific reference intervals  
*N. Brouwer (The Netherlands)*
10:30-12:30 ROOM 13a

SYMPOSIUM 9
New insights in amyloidosis
*Chairs: G. Palladini (Italy), S.O. Schönland (Germany)*

The clinical laboratory in the management of systemic amyloidosis: state of the art
G. Palladini (Italy)

Genetics of the amyloidogenic plasma cell clone: impact on clinical management
S.O. Schönland (Germany)

Assessment of MRD in AL amyloidosis
B. Paiva (Spain)

---

10:30-12:30 ROOM 13b

SYMPOSIUM 10
How to make EQA fit for purpose?
*Chairs: P. Meijer (Netherlands), C. Buchta (Austria)*

What are the fundamental aims of EQA?
C. Buchta (Austria)

The role of EQA in quality assurance of the extra-analytical phase
J. Cadamuro (Austria)

Patient results for “real-time” surveillance of pre-analytical and analytical stability
A.E. Solsvik (Norway)

Development of an External Quality Assessment (EQA) Programme for SARS-CoV-2 Ab
G. Davies (UK)

Assessing laboratory performance of hs-c-troponin with EQA data
M. van Schrojenstein Lantman (The Netherlands)
10:30-12:30  ROOM 14a

**SYMPOSIUM 11**

**Hemostasis**

*Chairs: B. Lammle (Germany), K. Vanhoorelbeke (Belgium)*

- Procoagulant COAT platelets: Mechanisms and clinical relevance
  *L. Alberio (Switzerland)*

- Monitoring of novel therapies of hemophilia in the clinical laboratory
  *S. Kitchen (UK)*

- Thrombotic thrombocytopenic purpura – from bench to bedside
  *K. Vanhoorelbeke (Belgium)*

- Diagnosis and laboratory-guided clinical management of anticoagulant rodenticides poisoning
  *M. Lenski (France)*

- Multicentre study on the comparison of methods for the measurement of anticoagulant activity in patients treated with DOAC (Direct Oral AntiCoagulants)
  *M. Vidali (Italy)*

---

10:30-12:30  ROOM 14c

**DGKL SYMPOSIUM**

**Autoimmune disorders of coagulation**

*Chairs: K. Lackner (Germany), T. Bakchoul (Germany)*

- Immune thrombocytopenia – diagnosis and treatment
  *T. Bakchoul (Germany)*

- Pathophysiology and Diagnosis of Antiphospholipid Syndrome
  *N. Müller-Calleja (Germany)*

- Acquired hemophilia – diagnosis and treatment
  *A. Tiede (Germany)*

---

12:30-14:00  HALL C1

**POSTER SESSION**

---

14:00-16:00  ROOM 14c

**SYMPOSIUM 12**

**New development in Diagnosis and therapy of dyslipidemia and CVD**

*Chairs: B. Nordestgaard (Denmark), A. von Eckardstein (Switzerland)*

- B. Nordestgaard
- A. von Eckardstein
Advances in lipid-lowering therapy through antibody-based and gene-silencing technologies
B. Nordestgaard (Denmark)

Measuring atherogenic lipoproteins that address residual cardiovascular risk beyond LDL-c
M. Langlois (Belgium)

The challenges of measuring apolipoprotein(a) and its relevance for patient management and patient outcome
C. Cobbaert (Netherlands)

HDL-Quo vadis?
A. von Eckardstein (Switzerland)

---

**VIEWPOINT 3**

15:30-16:30 ROOM 1

**Biomarkers of alcohol abuse in clinical and forensic use – strengths and limitations**
Chair: U. Ceglarek (Germany)

Carbohydrate deficient transferrin as marker for alcoholism, its use in comparison with ‘old’ indirect biomarkers
JPM. Wielders (Netherlands)

Ethylglucuronide (EtG) – the one and only (direct) marker of alcohol consumption?
H. Andresen-Streichert (Germany)

---

**VIEWPOINT 4**

17:00-18:00 ROOM 1

**Which future for HbA1c as biomarker of diabetes monitoring?**
Chair: E. Kilpatrick (UK)

HbA1c remains the gold standard
G. John (UK)

The future belongs to Time in Range and continuous glucose monitoring indications
D. Leslie (UK)
COMPANIES’ EDUCATIONAL WORKSHOPS TUESDAY, 12 APRIL

14.00-15.00   ROOM 1
EDUW 15 – ORTHO CLINICAL DIAGNOSTICS
Title: Chimeric Antigen Receptor (CAR)-T cell therapy: research findings, clinical applications, and markers to control cytokine release syndrome
Chair: Els Melis, EMEA Senior Marketing Manager Clinical Labs Assays, Ortho Clinical Diagnostics

Speakers:
Prof. Álvaro Urbano Ispizua, Director of the Institute of Hematology and Oncology of Hospital Clinic Barcelona and Full Professor of Medicine at the University of Barcelona.
Chimeric Antigen Receptor (CAR) – T cell therapy: from immunotherapy research to clinical applications in cancer treatment.
Cecilia Scarponi, EMEA Clinical Liaison, Ortho Clinical Diagnostics
Laboratory biomarkers for the investigation of CAR-T cells toxicity.

Learning objectives:
• The immunotherapy: mechanisms of action and targeted hematological malignancies
• The Patient: successful treatments and strategies to overcome side effects
• How laboratory tests can contribute to a favorable patient outcome? Which biomarkers are currently of interest to assess cytokine release syndrome and neurotoxicity associated with CAR-T cell therapy?

14.00-15.00   ROOM 13a
EDUW 17 – ABBOTT
Title: Achieving Measurably Better Healthcare… How to get started and achieve success through integrated clinical care initiatives

Speakers:
Tricia Ravalico, Director, Scientific Leadership and Education for Abbott, Core Diagnostics Executive Lead, UNIVANTS of Healthcare Excellence Program
Maria Salinas, PhD, Head of Laboratory, Hospital Universitari Saint Joan d’Alacant, Spain - 2020 UNIVANTS of Healthcare Excellence Global Winner
Rana Nabulsi, MD, Head Consultant on Healthcare Quality, Dubai Health Authority, UAE – 2020 UNIVANTS of Healthcare Excellence Awards, Global Distinction and Best of the Middle East

Learning objectives:
• Recognize, appreciate and emulate critical success factors and key attributes across successful integrated clinical care teams
• Define relevant key performance indicators that can be influenced and impacted by laboratory medicine and pathology leadership
• Highlight successful examples of award-winning best practices related to the Diabetes epidemic and COVID-19 pandemic.
• Identify opportunities to achieve and be recognized for measurably better healthcare performance
14.00-15.00 ROOM 13b

**EDUW 18 – SYMEX**

**Title:** Towards a smarter lab with digitally enhanced solutions  
*Chair:* Theo Hofman – Sysmex Europe GmbH

**Speakers:**
Jean-Marc Giannoli – Biogroup Laboratories, Neuville-sur-Saône, France  
Value of combining QC and patient results for decision support on analytical performance  
Dr. Patrick Cohen – Geneva University Hospital, Switzerland  
Biomedical insights beyond the numbers  
Koray Yurdakul, Sysmex Turkey

**Leveraging virtual and mobile learning experiences in healthcare**

**Learning objectives:**
In the laboratory of today, besides global challenges, many regulatory and organisational demands impact the daily work. Oftentimes it can be perceived as a burden, but it also gives new opportunities to improve the laboratory’s quality, streamline processes and find ways to do things differently. With digitally enhanced solutions, information from multiple sources can be consolidated easily for a more holistic approach and lead to new insights. In this workshop, the synergy between existing and new cornerstones of monitoring the quality of analytical processes is demonstrated, explained how the use of expert software can support in clinical decision making and in which ways digital learning experiences can bring and maintain the knowledge of the laboratory staff on a high level while saving time and costs and reduce environmental impact.

---

14.00-15.00 ROOM 14a

**EDUW 19 – ROCHE**

**Title:** Diagnostic Innovation Drivers  
*Chair:* Victor Jeger, PD Dr.med. MD, PhD, Roche Diagnostics

**Speakers:**
Prof. Dr. med. Michael Vogeser, Institute of Laboratory Medicine, Hospital University of Munich, Germany  
Use of Mass Spectrometry in Clinical Diagnostics  
Prof. Prof. Charlotte Teunissen, Universitair Medische Centra Amsterdam, The Netherlands  
Timely and accurate differential diagnosis of patients with cognitive impairment

**Learning objectives:**
Mass spectrometry is a powerful analytical technology that has evolved from a research tool to a complementary platform in routine clinical laboratories. Unlike established methods such as immunoassays, MS allows true multiplexing, highest specificity of detection and unsurpassed reliability due to the use of standard compounds labelled with stable isotopes. With increasing clinical applications, the focus is on clinical chemistry and more recently microbiology. The main objective of this presentation is to give an overview of the current and developing clinical applications of MS.

Dementia affects millions of people worldwide and is expected to triple by 2050. Alzheimer’s disease (AD) is the most common form of dementia and may contribute to 50-60% of cases. In 2015 the overall global cost of dementia was already USD 818 billion and is expected to increase to USD 2 trillion in 2030. Early diagnosis can benefit patients and society as a whole. Confirming a diagnosis of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) is important and often a relief for the individual and their loved ones. Receiving a diagnosis early enables patients to make changes to their diet and lifestyles which may slow the decline in their cognitive functions. Two of the main hallmark signs of AD are the “plaques” and “tangles” that develop in the brain, caused by the build-up of, respectively, amyloid and tau proteins. The accumulation of amyloid beta and tau starts decades prior to symptom onset. CSF biomarkers support early and accurate diagnosis of MCI and AD, as these biomarkers reflect the specific pathological accumulation of amyloid beta in plaques and tau in neurofibrillary tangles.
**15.30-16.30 ROOM 13a**

**EDUW 21 – GMT SCIENCE**

**Title:** Faecal metagenomics analysis made available at the medical lab to empower clinical diagnosis & management

**Chair:** Etienne Formstecher – CEO, GMT, Paris, France

**Speakers:**
- Fay Betsou – Scientific Advisor, Laboratoire National de Santé, Luxembourg
- Francisco Guarner – Member of the Digestive System Research Unit, University Hospital Vall d’Hebron; Consultant of Gastroenterology, Teknon Medical Centre, Barcelona, Spain
- David Petiteau – Translational microbiomics, GMT, Paris, France

**Q&A and discussion**

**Learning objectives:**

The gut microbiota is now recognized as a novel therapeutic target in many clinical contexts. However, due to the lack of a reliable tool to characterize it, the proposed treatments can neither be adapted to the specific needs of the patient nor evaluated in terms of response. The educational workshop will present how analysis of the faecal metagenome at the medical laboratory is now possible thanks to the combination of reliable, standardized and reproducible pre-analytical and analytical techniques with robust bioinformatics methods. By putting in place this solution, medical laboratories can empower clinical diagnosis and management in various situations, including very common ones at the medical consultation where patients express gut complaints.
**EDUW 22 – SEBIA**

**Title:** What’s new in Minimal Residual Disease testing for Multiple Myeloma?

**Chair:** Dr. Martijn van Duijn, Erasmus Medical Center, Rotterdam, The Netherlands

**Speakers:**
- Dr. Thomas Dejoie, Biochemical Laboratory, University Hospital of Nantes, France
- Dr. Hans Jacobs, Radboud University Medical Center, Nijmegen, The Netherlands

**Learning objectives:**
- Why do we need MRD for patients?
- How do we process MRD in 2021?
- Why do we need alternative to the MRD bone marrow evaluation?
- Understand the principle of mass spectrometric measurements of clonotypic peptides (bottom-up MS).

---

**EDUW 23 – SNIBE**

**Title:** An update on tumor markers from the general aspects to their clinical uses

**Chair:** Prof. Tomris Ozben, Dept. of Clinical Biochemistry, Medical Faculty, University of Akdeniz, Antalya, Turkey

**Speakers:**
- Prof. Tomáš Zima - Institute of Clinical Chemistry & Laboratory Diagnosis, First Faculty of Medicine, Charles University Prague – Czech Republic
- Prof. Tomris Ozben - Dept. of Clinical Biochemistry, Medical Faculty, University of Akdeniz, Antalya, Turkey

**Methods to measure tumor markers. Clinical uses of tumor markers for malignant diseases**

**Learning objectives:**
- Classification of tumor markers
- Characteristics of ideal tumor markers
- Methods to measure tumor markers
- Limitations of tumor marker tests
- Benign conditions associated with rise in tumor markers
- Clinical uses of tumor markers for malignant diseases (clinical cases)

---

**EDUW 26 – SIEMENS HEALTHINEERS**

**Title:** Non-Invasive Assessment of Liver Fibrosis in Chronic Liver Diseases

**Chair:** Jean Charles Clouet – Siemens Healthineers, EMEA Clinical Marketing

**Speaker:**
- Professor Jörn M. Schattenberg – Metabolic Liver Research Program, University Medical Center Mainz

**Learning Objectives:**
- Educate on the current growing burden of disease due to NAFLD/NASH
- Learn how non-invasive testing can help identify patients at risk of NASH progression
- Understand how clinicians can implement available patient pathways to improve referrals and decrease costs
Integrative Diagnostics as the Key Driver for Intelligent Systems in Medicine

**S. Schönberg (Germany)**

---

Stefan Schönberg

is the Director of the Department of Radiology and Nuclear Medicine at the University Hospital Mannheim and Chair of Radiology and Nuclear Medicine at the Mannheim Medical Faculty of the University of Heidelberg. He earned his degree in medicine from Ruprecht-Karls-University in Heidelberg, Germany in 1995. In 2002, he received his doctorate in Diagnostic Radiology at the Medical Faculty of the University of Heidelberg.

Professor Dr. Schönberg is a specialist in Diagnostic Radiology and is a strong advocate for Integrated and Data-Driven Diagnostics. He has set significant benchmarks for fast and precise imaging diagnostics with the clinical advancement of parallel imaging and multi-channel technology in high-field magnetic resonance imaging (MRI). By combining morphological and functional MRI and CT diagnostics, he has established methods for a comprehensive non-invasive characterization of organ diseases. During his German Radiological Society (DRG) presidency from 2017 - 2019, he pioneered the International Radiomics Platform, which enables multi-center data-driven research projects.

Main research interests:
- Integrated Diagnostics
- Vascular and abdominal imaging
- Functional MRI
- High-field MRI
- Oncological imaging
- Radiomics and Artificial Intelligence
10:30-12:30 ROOM 13a

SYMPOSIUM 13
Porphyrias – integration of laboratory medicine and clinical care (A symposium in memorial of the 140 years anniversary of the birth of Hans Fischer)
Chairs: S. Sandberg (Norway), A.K. Aarsand (Norway)

Hans Fischer and his role in developing the field of porphyria
S. Sandberg (Norway)

Practical guidelines on how to diagnose the porphyrias
A.K. Aarsand (Norway)

Regulation of the haem biosynthesis
J. Philips (USA)

Newer treatment options for porphyria
J.C. Deybach (France)

10:30-12:30 ROOM 5

SYMPOSIUM 14
Advances in IQC tools and techniques
Chairs: T. Badrick (Australia), E. Kilpatrick (UK)

How is conventional QC practised now and how can it be improved?
E. Kilpatrick (UK)

The importance of demonstrating commutability of reference materials with IQC
V. Delatour (France)

Patient Based Real Time QC – an introduction
T. Badrick (Australia)

PBRTQC – implementing into routine practice validation and simulation
A. Bietenbeck (Germany)
**SYMPOSIUM 15**

**High-sensitivity troponins and beyond**
*Chairs: S. Wittfooth (Finland), R. Christenson (USA)*

Analytical aspects of high-sensitivity troponin assays: Impact on Clinical Application  
*R. Christenson (USA)*

High-sensitivity troponins in clinical use  
*P. Collinson (UK)*

Troponin fragments for better specificity?  
*S. Wittfooth (Finland)*

---

**SYMPOSIUM 16**

**Health platforms of the future and clinical relevance of interoperability**  
*Chair: C. Cobbaert (Netherlands)*

Defining Interoperability in Healthcare with HL7-FHIR and understanding the potential transformation of pathology  
*G. Grieve (Australia)*

The value of interoperable communication of pathology requests and results  
*K. Sikaris (Australia)*

Illuminating the Black Box - why and how to do explainable Artificial Intelligence in a medical setting  
*A. Tolios (Austria)*

---

**SYMPOSIUM 17**

**New trends in standardization**  
*Chairs: P. Gillery (France), E. Cavalier (Belgium)*

Standardization of bone markers  
*E. Cavalier (Belgium)*

Standardization in fecal immuno-testing  
*S. Benton (UK)*

Traceability chains in Therapeutic drug monitoring: scope, limitations and state of the art  
*C. Seger (Switzerland)*

Standardization in glucose monitoring  
*G. Freckmann (Germany)*
10:30-12:30 ROOM 14c

DGKL SYMPOSIUM
Personalised medicine in allergy diagnostics
Chair: H. Renz (Germany)

Molecular Diagnosis and Digital Health for Precision Allergology
P. Matricardi (Germany)

Asthma and COPD diagnostics – lessons learned from multi-centre big data analysis
H. Renz (Germany)

The Janus-faced nature of viral infections in asthma
C. Skevaki (Germany)

Chip-based diagnosis for personalized treatment
K. Niespodziana (Austria)

12:30-14:00 HALL C1
POSTER SESSION

14:00-16:00 ROOM 14c

SYMPOSIUM 18
Consequences of IVDR Regulations on Laboratory Medicine
Chairs: C. Cobbaert (Netherlands), P. Monaghan (UK)

The In Vitro Diagnostics Regulation – the perspective of the European Commission
O. Tkachenko (Belgium)

Consequences of the IVDR 2017/746 for the IVD-industry
O. Bisazza (Belgium), I. Slobodeaniuc (Belgium)

Consequences of the IVDR 2017/746 for Notified Bodies
A.F. Stange (Japan)

Consequences of the IVDR 2017/746 for Laboratory Professionals
C. Cobbaert (Netherlands)
VIEWPOINT 6
Regulating direct-to-consumer testing 2.0: Protecting the consumer
Chair: B. Gouget (France)

Introduction: What is Direct-to-Consumer (D2C or DTC), how to increase Public Awareness
B. Gouget (France)

Opportunities for decentralized testing in modern healthcare and dangers vs benefits of DTC
J.H. Nichols (USA)

Advocacy for appropriate regulation of biological tests sold directly to consumers
M. Vaubourdolle (France)
EDUW 29 – ORTHO CLINICAL DIAGNOSTICS

Title: Sustainable Laboratory Medicine: Prepare for the future now!
Chair: Dr. Bernard Gouget, Ph.D – ex-Assistant Professor at the University Hospital in Paris Descartes, President-Healthcare Division Executive Committee, Comité Français d'accréditation (Cofrac), President, National Committee for the selection of Reference Laboratories, Ministry of Health

Speakers:
Professor Damien Gruson – Head of the department of Laboratory Medicine of the Cliniques Universitaires Saint Luc – Brussels, Belgium
Sustainable Laboratory Medicine: Myth or reality?
Jordi Trafí-Prats – Senior Director EMEA Marketing at Ortho Clinical Diagnostics
Sustainable Laboratory Medicine: we all have a role to play.

Learning objectives:
In the coming years, the impact of sustainability will be increasingly felt in healthcare. From the implications of legislation to the growing number of environmentally conscious investors, this is a topic which is set to shape the future direction of hospitals, labs and blood banks.
Professor Damien Gruson as a member of the Division on Emerging Technologies of IFCC, is sharing his perspective and will be providing some pragmatic approaches and share experiences from the perspective of the Clinical Laboratory. Jordi Trafí-Prats will demonstrate how the industry can and should contribute to assure Laboratories are equipped with sustainable solutions.

EDUW 31 – ABBOTT

Title: Driving Healthcare Transformation Through Clinical Decision Support

Speakers:
Dr Janne Cadamuro – Department of Laboratory Medicine, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria
How to tackle laboratory underuse using Clinical Decision Support Systems (CDSS)
Françoise Luyckx – Pharmacist biologist, Laboratory Manager and Coordinator of new projects, member of the “Artificial Intelligence” working group, Coordinator of CDS project and IT trainer, University Hospital of Liege (CHU de Liège), Belgium
Romy Gadisseur – Pharmacist biologist, Head of the Laboratory of Automated Biochemistry, Department of Clinical Chemistry, University Hospital of Liege (CHU de Liège), Belgium

CHU Liege: Impacting CKD patients by leveraging a Clinical Decision Support
Abbott Speaker
Florian Lange, Director AelinIQ & Enterprise Solutions EMEA
Transformation of healthcare through digital solutions

Learning objectives:
• Recognize the value of clinical decision support and artificial intelligence in achieving measurable better healthcare.
• Understand how the use of a clinical decision support solution enabled the University Hospital of Salzburg and in CHU Liege to address unmet needs for microcytic anaemia, diabetes and chronic kidney disease.
• Connect the dots on how to get started and drive digital transformation into better healthcare outcomes
**EDUW 32 – SIEMENS HEALTHINEERS**

*Title: The Evolving Role of Artificial Intelligence in Laboratory Testing*

**Speakers:**
- Raj Gopalan, MD, MSIS, Head of Global Clinical Decision Support and Chief Medical Informatics Officer, Siemens Healthineers, Tarrytown, NY, USA
- Sarah Wheeler, Assistant Professor, PhD, FACB, CC, Associate Medical Director, Clinical Immunopathology; Medical Director, Automated Laboratory, UPMC Mercy; and Medical Director, Automated Laboratory, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

**Perspective from data science (AI/ML):**
- Define artificial intelligence and machine learning in the context of laboratory medicine.
- Discuss the relevance of artificial intelligence and machine learning in laboratory medicine and diagnostics.
- Understand the potential value of artificial intelligence in laboratory diagnostics.

**EDUW 33 – ROCHE**

*Title: Diabetes and the heart*

*Chair: Rolf Hinzmann, MD, PhD, Head of Medical Science – Roche Diabetes Care, Mannheim, Germany*

**Speakers:**
- Prof. Christophe Meune, M.D., PhD, Cardiology Department, Avicenne University Hospital, Paris, France
- Prof. Dr. Stephan Jacob – Praxis für Prävention und Therapie, Villingen-Schwenningen, Germany

**Early identification of Heart Failure in T2D: Intervention for improving patient outcomes**

**Integrated Personal Diabetes Management**

**Learning objectives:**
- For many years, clinical studies could not show that lowering glucose in patients with type 2 diabetes leads to better macrovascular outcomes. In the past few years, new data have shown that treatment with two classes of drugs developed as “glucose-lowering agents,” SGLT2 inhibitors and GLP-1 receptor agonists can reduce macrovascular and renal complications. These studies have prompted debate about the main aim of type 2 diabetes management. In this scientific session eras of diabetes management are described according to the treatment recommendations, moving from a pure glucocentric view into the present cardio-renal outcome-oriented approach, this has been endorsed by major diabetes and cardiology societies. Type 2 Diabetes Patients are at high risk of developing cardiovascular disease. New evidence on the use of natriuretic peptides supports the identification of patients with high cardiovascular risk, for risk stratification and optimization of cardio protective treatment.

**EDUW 35 – BD**

*Title: Preanalytical POCT Errors – What impact do they have?*

*Chair: Dr Brendan Meyer - Senior Manager, Medical Affairs Europe, Integrated Diagnostic Solutions, BD Life Sciences*

**Speakers:**
- Professor Peter Luppa, Institute for Clinical Chemistry and Pathobiochemistry, Technische Universität München, Munich, Germany
- Dr Andrei Tintu, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands
- Dr Antonio Buño Soto, Pathology Department, La Paz Hospital, Madrid, Spain

**Learning objectives:**
- There are erroneous POCT results due to blood sample quality, which are not detected by the POCT device.
- How preanalytical errors not detected by the POCT device can impact on patient care.
- POCT preanalytical errors can impact on hospital resources and budgets.
IFCC WorldLab

SEOUl 2022

24th INTERNATIONAL CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

June 26-30, 2022
Coex, Seoul, Korea
SCIENTIFIC PROGRAMME THURSDAY, 14 APRIL

9:00-10:00
PLENARY LECTURE
Chair: K. Adeli (Canada)

Towards next generation diagnostics by X-omics
A. Van Gool (Netherlands)

10:00-10:30
Break

Alain van Gool

is professor Personalized Healthcare and heads the Translational Metabolic Laboratory at the Radboud university medical center, with a strong passion in the application of biomarkers in translational medicine and personalized healthcare. After his study (biochemistry, 1991) and PhD (molecular biology, 1996) Alain worked at a mix of academia, pharmaceutical industries, applied research institutes, university medical centers in Europe, Asia and USA. He has been leading technology-based biomarker laboratories, cross-functional expert teams, therapeutic project teams and public-private consortia, many of which were focused on the discovery, development and implementation of translational biomarkers in a variety of therapeutic areas. His technical expertise resides most strongly in molecular profiling (various Omics approaches), analytical biomarker development and applications in translational scientific research.

Alain is a strong believer of open innovation networks and thrives to work with specialists to translate basic research to applied science. With that background, he currently also acts as Strategic Advisor to the Executive Board of Radboudumc, co-coordinates the Radboudumc Technology Centers, is Scientific Lead Technologies of DTL (the Dutch Techcenter for Life Sciences), is Chair Biomarker Platform of EATRIS (the European infrastructure for Translational Medicine), is co-initiator of Health-RI (the Netherlands Health Research Infrastructure for Personalized Medicine and Health), and Project leader and PI of the Netherlands X-omics Initiative, thus contributing to the organisation and coordination of local, national and European technology infrastructures. Complementing his daily work, he enjoys contributing to scientific advisory boards of start-up entrepreneurs, multinational companies, translational organisations, funding agencies and conference organisers.
10:30-12:30    ROOM 14a
SYMPOSIUM 19
New diagnostic approaches in Laboratory Medicine
Chairs: M. Plebani (Italy), S. Bernardini (Italy)

Extracellular vesicles in clinical diagnostics
K. Witwer (USA)

miRNA in clinical diagnostics – can artificial intelligence make the difference?
A. Keller (Germany)

Wearable biosensors
W. Gao (USA)

Comparison of reference values for small extracellular particles in a healthy study cohort using Nanoparticle Tracking Analysis (NTA) before and after particle isolation by different isolation methods
B. Betz (Germany)

Analysis of volatile organic compounds (VOCs) in the breath of colorectal cancer (CRC) subjects by Cyranose ‘electronic nose
A. Bonari (Italy)

10:30-12:30    ROOM 5
SYMPOSIUM 20
Autoimmune Encephalitis
Chairs: A. Vincent (UK)

Overview and pathophysiology
A. Vincent (UK)

Autoimmune encephalopathies in Neurology
M. Gastaldi (Italy)

Autoimmune encephalopathies in Psychiatry
J. Cunningham (Sweden)
10:30-12:30  ROOM 13a

**SYMPOSIUM 21**

Urinalysis: a new look at old tests
*Chairs: J. Delanghe (Belgium), W. Hofmann (Germany)*

Modern urine test strip technology
*J. Delanghe (Belgium)*

Automated urinalysis
*G. Previtali (Italy)*

The Revised European Urinalysis Guidelines
*T. Kouri (Finland)*

New approaches to the study bladder cancers using molecular genetic methods and fluorescence analysis
*K. Dubayová (Slovakia)*

10:30-12:30  ROOM 13b

**SYMPOSIUM 22**

Young Scientist Session
*Chairs: S. Fares Taie (Argentina), T. Pillay (South Africa)*

Motivation in the Clinical Laboratory
*S. Fares Taie (Argentina)*

Productivity Tools for Young Scientist Professional
*I.W. Masţufa (Indonesia)*

Career management for Young Laboratory Scientists
*G. Sancesario (Italy)*

Conflict Management amongst Young Laboratory Scientists
*A. Rampul (South Africa)*

10:30-12:30  ROOM 1

**SYMPOSIUM 23**

How does Point of Care Testing change the clinical pathways?
*Chairs: A. Khan (USA), E. Jacobs (USA)*

Point-of-care Testing: a win-win for all players
*A. Khan (USA)*

Is internal (and external?) quality control necessary for POCT?
*E. Jacobs (USA)*
The role of POC-testing in the clinical pathway of diagnosing SARS-CoV-2 infection
M.C. Tollanes (Norway)

Testing for Anti-Mullerian Hormone: analytical performances and usability of a Point-of-Care assay
D. Gruson (Belgium)

Hemolysis detection with the H-10 Hemcheck device in whole blood and plasma STAT samples
A. Garcia Osuna (Spain)

10:30-12:30 ROOM 14c

DGKL SYMPOSIUM
Emerging infectious diseases – impact of laboratory diagnosis
Chair: M. Klouche (Germany)

Infectious disease surveillance – implications of diagnostic screening strategies
R. Dürrwald (Germany)

High-throughput LAMP-sequencing for diagnosis of infectious diseases
J. Schmid-Burgk (Germany)

Setting up external quality control measures for SARS-CoV-2 during pandemics
V. Haselmann (Germany)

12:30-13:30 ROOM 1

CLOSING CEREMONY

Closing remarks
Euromedlab Munich 2021 President, K. Lackner
Euromedlab Munich 2021 Chair, M. Neumaier
IFCC President, K. Adeli
EFLM President, T. Ozben

Presentation of 3rd EFLM Strategic Conference
T. Ozben, Chair of the Conference

Presentation of WorldLab-Euromedlab Roma 2023
S. Bernardini, President of the Congress

Farewell Italian Cocktail
25TH INTERNATIONAL CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

25TH EUROPEAN CONGRESS OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE

55TH CONGRESS OF THE ITALIAN SOCIETY OF CLINICAL BIOCHEMISTRY AND CLINICAL MOLECULAR BIOLOGY

ORGANISING SECRETARIAT
Via Carlo Farini 81 - 20159 Milano (Italy)
Phone: +39 02 66802323
E-mail: info@2023roma.org
Innovation based on your needs

Creating the future of labs

Improve your efficiency and competitiveness with the help of the pioneer in integration of laboratory solutions, setting new standards in the evolution of future diagnostics.

WHERE CARE LEADS

Meet us at the Roche booth, and experience Roche's Integrated Core Lab and Digital Diagnostics live.

diagnostics.roche.com/eml

Scan code for more information
## CLOSED MEETINGS

### SATURDAY, 9 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-17:00</td>
<td>IFCC SD-EC – Chair: P. Gillery</td>
<td>Room Wörthsee - Mezzanine</td>
</tr>
<tr>
<td>09:00-17:00</td>
<td>IFCC CPD-EC - Chair: T. Pillay</td>
<td>Room Pilsensee - Mezzanine</td>
</tr>
</tbody>
</table>

### SUNDAY, 10 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-12:00</td>
<td>IFCC CPD-EC - Chair: T. Pillay</td>
<td>Room Pilsensee - Mezzanine</td>
</tr>
<tr>
<td>09:00-12:00</td>
<td>EFLM Executive Board – Chair: T. Ozben</td>
<td>Room Watzmann – 2nd floor</td>
</tr>
<tr>
<td>09:00-12:00</td>
<td>IFCC SD-EC – Chair: P. Gillery</td>
<td>Room Wörthsee – Mezzanine</td>
</tr>
<tr>
<td>09:00-16:00</td>
<td>IFCC TF- GRID – Chair: J. Zierk</td>
<td>Room Staffelsee – Mezzanine</td>
</tr>
<tr>
<td>09:30-13:00</td>
<td>IFCC C-RIDL – Chair: T. Streichert</td>
<td>Room Jochberg – 2nd floor</td>
</tr>
<tr>
<td>12:30-17:30</td>
<td>EFLM WG-PFLM – Chair: S. Jovicic</td>
<td>Room Watzmann – 2nd floor</td>
</tr>
<tr>
<td>13:00-16:00</td>
<td>IFCC Council</td>
<td>Room Ostersee a+b+c – 2nd floor</td>
</tr>
<tr>
<td>14:00-16:00</td>
<td>EFLM WG-CM – Chair: P. Laitinen</td>
<td>Room Zugspitze – 2nd floor</td>
</tr>
</tbody>
</table>

### MONDAY, 11 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-13:00</td>
<td>IFCC C-PR - Chair: R. Erasmus</td>
<td>Room Staffelsee – Mezzanine</td>
</tr>
<tr>
<td>08:30-13:00</td>
<td>IFCC ejIFCC - Chair: J. Kappelmaier</td>
<td>Room Kochelsee – 2nd floor</td>
</tr>
<tr>
<td>09:00-11:00</td>
<td>IFCC TF-CM – Chair: T. Ravalico</td>
<td>Room Königssee – 2nd floor</td>
</tr>
<tr>
<td>09:00-17:00</td>
<td>IFCC ETD-EC – Chair: S. Bernardini</td>
<td>Room Ostersee a – 2nd floor</td>
</tr>
<tr>
<td>09:00-17:00</td>
<td>IFCC WG-CDT – Chair: J. Deenamode</td>
<td>Room Hirschberg – 2nd floor</td>
</tr>
<tr>
<td>09:00-13:00</td>
<td>IFCC W-ID - Chair: C. Seger</td>
<td>Room Pilsensee – Mezzanine</td>
</tr>
<tr>
<td>11:30-13:30</td>
<td>IFCC Corporate Members – Chair: J. Passarelli</td>
<td>Room Königssee – 2nd floor</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>EFLM WG-DE - Chair: D. Cerne</td>
<td>Room Zugspitze – 2nd floor</td>
</tr>
<tr>
<td>12:30-15:00</td>
<td>IFCC PAPP A - Chair: H. Lennart-Friist</td>
<td>Room Jochberg – 2nd floor</td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>Open meeting together with the</td>
<td>Room Ostersee b+c – 2nd floor</td>
</tr>
<tr>
<td>12:45-14:30</td>
<td>EFLM General Meeting - Chair: T. Ozben</td>
<td>Room 5 - Ground floor</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>IFCC C-EBLM – Chair: A. Zemlin</td>
<td>Room Eibsee – 2nd floor</td>
</tr>
<tr>
<td>14:00-18:00</td>
<td>IFCC EMD EC - Chair N. Rifai</td>
<td>Room Kochelsee – 2nd floor</td>
</tr>
<tr>
<td>15:00-17:30</td>
<td>EFLM C-P + WG-R - Chair: E. Homsak/I. Rako</td>
<td>Room Königssee – 2nd floor</td>
</tr>
</tbody>
</table>
**CLOSED MEETINGS**

### TUESDAY, 12 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-13:00</td>
<td>IFCC ETD-EC - Chair: S. Bernardini</td>
<td>Room Ostersee a – 2nd floor</td>
</tr>
<tr>
<td>09:00-11:00</td>
<td>IFCC WG-CGM – Chair: G. Freckman</td>
<td>Room Eibsee – 2nd floor</td>
</tr>
<tr>
<td>09:00-13:00</td>
<td>IFCC TF-YS - Chairs: S. Fares Taie - G. Sancesario</td>
<td>Room Pilsensee – Mezzanine</td>
</tr>
<tr>
<td>09:00-13:30</td>
<td>IFCC C-EUBD – Chair: E. English</td>
<td>Room Staffelsee – Mezzanine</td>
</tr>
<tr>
<td>12:30-14:30</td>
<td>EFLM C-C – Chair: D. Rajdl</td>
<td>Room Zugspitze – 2nd floor</td>
</tr>
<tr>
<td>12:30-14:00</td>
<td>IFCC Lab Week - Chairs: K. Adeli, R. Erasmus</td>
<td>Room Wörthsee – Mezzanine</td>
</tr>
<tr>
<td>14:00-17:00</td>
<td>IFCC WG-SCST - Chair: A. South</td>
<td>Room Pilsensee – Mezzanine</td>
</tr>
<tr>
<td>14:00-17:30</td>
<td>IFCC C-BM - Chair: E. Cavalier</td>
<td>Room Eibsee – 2nd floor</td>
</tr>
<tr>
<td>14:00-17:00</td>
<td>EFLM WG-CPE – Chair: E. Sozmen</td>
<td>Room Watzmann – 2nd floor</td>
</tr>
<tr>
<td>15:00-17:30</td>
<td>EFLM TFG-PMU - Chair: A. Coskun</td>
<td>Room Zugspitze – 2nd floor</td>
</tr>
</tbody>
</table>

### WEDNESDAY, 13 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-17:00</td>
<td>IFCC EB – Chair: K. Adeli</td>
<td>Room Pilsensee – Mezzanine</td>
</tr>
<tr>
<td>12:30-13:30</td>
<td>EFLM C-S - Chair: M. Langlois</td>
<td>Room Zugspitze – 2nd floor</td>
</tr>
<tr>
<td>14:00-18:00</td>
<td>IFCC WG-PCT – Chair: V. Delatour</td>
<td>Room Wörthsee – Mezzanine</td>
</tr>
</tbody>
</table>

### THURSDAY, 14 APRIL 2022

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-12:30</td>
<td>IFCC WG-APO – Chair: C. Cobbaert</td>
<td>Room Königssee – 2nd floor</td>
</tr>
<tr>
<td>09:00-17:00</td>
<td>IFCC EB – Chair: K. Adeli</td>
<td>Room Pilsensee – Mezzanine</td>
</tr>
<tr>
<td>13:30-17:00</td>
<td>EFLM WG-TE – Chair: C. Cobbaert</td>
<td>Room Königssee – 2nd floor</td>
</tr>
<tr>
<td>SPEAKERS &amp; CHAIRS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aarsand Aasne K.</td>
<td>Norwegian Porphyria Centre, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Norway</td>
<td></td>
</tr>
<tr>
<td>Adeli Khosrow</td>
<td>IFCC President, Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, Canada</td>
<td></td>
</tr>
<tr>
<td>Alberico Lorenzo</td>
<td>Department of Hematology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland</td>
<td></td>
</tr>
<tr>
<td>Alcantara Flavio</td>
<td>University of San Paolo, Brazil</td>
<td></td>
</tr>
<tr>
<td>Andersen-Streichert</td>
<td>Hilk Institute for Legal Medicine Department of Toxicology, University Hospital Cologne, Germany</td>
<td></td>
</tr>
<tr>
<td>Badrick Tony</td>
<td>Royal College of Pathologists of Australasia Quality Assurance Programs, Sydney</td>
<td></td>
</tr>
<tr>
<td>Bakhoum Tamam</td>
<td>Institute for Clinical and Experimental Transfusion Medicine (IKET), University Hospital Tuebingen, Germany</td>
<td></td>
</tr>
<tr>
<td>Benton Sally</td>
<td>Berkshire and Surrey Pathology Services, Royal Surrey County Hospital, Guildford, UK</td>
<td></td>
</tr>
<tr>
<td>Bernardini Sergio</td>
<td>University of Tor Vergata, Dept. of Experimental Medicine, Rome, Italy</td>
<td></td>
</tr>
<tr>
<td>Betz Boris</td>
<td>Department of Clinical Chemistry and Laboratory Diagnostics, Jena University Hospital, Germany</td>
<td></td>
</tr>
<tr>
<td>Bietenbeck Andreas</td>
<td>Institut für Laboratoriumsmefizin, Medizinische Mikrobiologie und Technische Hygiene, München Klinik, Germany</td>
<td></td>
</tr>
<tr>
<td>Bisazza Oliver</td>
<td>Director General, Industrial Policies, MedTech Europe</td>
<td></td>
</tr>
<tr>
<td>Blankenberg Stefan</td>
<td>University Hospital Hamburg-Eppendorf, University Heart &amp; Vascular Center Hamburg, Clinic for Cardiology, Germany</td>
<td></td>
</tr>
<tr>
<td>Bohn Mary Kathryn</td>
<td>The Hospital for Sick Children, Toronto, Canada</td>
<td></td>
</tr>
<tr>
<td>Bonari Alessandro</td>
<td>Clinical Biochemistry Scientist, General Laboratory of Careggi University Hospital, Italy</td>
<td></td>
</tr>
<tr>
<td>Borchers Christoph</td>
<td>Director, Department of Oncology, McGill University, Segal Cancer Proteomics Centre</td>
<td></td>
</tr>
<tr>
<td>Brouwer Nannette</td>
<td>Diagnos-tIQ, Laboratory for Clinical Chemistry and Hematology, Hoorn, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>Buchta Christoph</td>
<td>ÖQUASTA, EQALM, Vienna, Austria</td>
<td></td>
</tr>
<tr>
<td>Cadamuro Janne</td>
<td>University Hospital Salzburg, Paracelsus Medical University Department of Laboratory Medicine, Salzburg, Austria</td>
<td></td>
</tr>
<tr>
<td>Cappabianca Salvatore</td>
<td>L. Vanvitelli, Campania University, Italy</td>
<td></td>
</tr>
<tr>
<td>Cavalier Etienne</td>
<td>Department of Clinical Biology, University Hospital of Liege, Belgium</td>
<td></td>
</tr>
<tr>
<td>Cegharek Uta</td>
<td>University Hospital Leipzig, Germany</td>
<td></td>
</tr>
<tr>
<td>Chavakis Triantafyllos</td>
<td>Institut für Klinische Chemie und Laboratoriumsmefizin, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Germany</td>
<td></td>
</tr>
<tr>
<td>Christenson Robert</td>
<td>University of Maryland School of Medicine, Department of Pathology, University of Maryland Medical Center, Labs of Pathology, Baltimore, USA</td>
<td></td>
</tr>
<tr>
<td>Cobbaert Christa</td>
<td>Afdeling Klinische Chemie en Laboratorygenesekunde</td>
<td>LUMC, Leiden, The Netherlands</td>
</tr>
<tr>
<td>Collinson Paul</td>
<td>St George's NHS University Hospitals NHS Foundation Trust and St George's University of London, UK</td>
<td></td>
</tr>
<tr>
<td>Constantinescu Stefan N</td>
<td>Ludwig Institute for Cancer Research Brussels and Oxford and de Duve Institute, Université catholique de Louvain, Belgium</td>
<td></td>
</tr>
<tr>
<td>Coriu Daniel</td>
<td>Center of Hematology and Bone Marrow Transplant, Fundeni Clinical Institute, University of Medicine and Pharmacy ”Carol Davila”, Bucharest, Romania</td>
<td></td>
</tr>
<tr>
<td>Coskun Abdurrahman</td>
<td>Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey</td>
<td></td>
</tr>
<tr>
<td>Cowie Martin</td>
<td>European Society of Cardiology Digital Health Committee, London, UK</td>
<td></td>
</tr>
<tr>
<td>Cunningham Janet</td>
<td>Dept of Medical Sciences, Psychiatry, Uppsala University, Uppsala Sweden / Dept Neurosciences, Karolinska Institute, Stockholm Sweden</td>
<td></td>
</tr>
<tr>
<td>Delanghe Joris</td>
<td>Ghent University, Belgium</td>
<td></td>
</tr>
<tr>
<td>Delatour Vincent</td>
<td>LNE, Paris, France</td>
<td></td>
</tr>
<tr>
<td>Deybach Jean-Charles</td>
<td>French Reference Center for Porphyrias University Paris European Porphyria Netwok, Paris, France</td>
<td></td>
</tr>
<tr>
<td>Dubavová Katarína</td>
<td>Pavol Josef Safarik University in Kosice, Medical Faculty, Slovakia</td>
<td></td>
</tr>
<tr>
<td>Dürwald Ralf</td>
<td>Robert Koch Institute, Department of Infectious Diseases, Berlin, Germany</td>
<td></td>
</tr>
<tr>
<td>Duschl Wolfgang</td>
<td>Christiana Albertina University, Astrophysics Kiel, Germany</td>
<td></td>
</tr>
<tr>
<td>Fares Taie Santiago</td>
<td>IFCC TF-YS</td>
<td></td>
</tr>
<tr>
<td>Forni Lui</td>
<td>Department of Clinical &amp; Experimental Medicine, School of Biosciences &amp; Medicine, University of Surrey, UK</td>
<td></td>
</tr>
<tr>
<td>Freckmann Guido</td>
<td>Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Germany</td>
<td></td>
</tr>
<tr>
<td>Fröhlich Matthias F</td>
<td>Department of Radiology and Nuclear Medicine, University Medical Centre Mannheim</td>
<td></td>
</tr>
<tr>
<td>Fuchsjaeger Michael</td>
<td>Department of Radiology, Medical University Graz, Austria</td>
<td></td>
</tr>
<tr>
<td>Galván Raquel</td>
<td>Laboratory Medicine Department, Virgen Macarena University Hospital, Seville, Spain</td>
<td></td>
</tr>
<tr>
<td>Gao Wei</td>
<td>California Institute of Technology, Pasadena, USA</td>
<td></td>
</tr>
<tr>
<td>Garcia Osuna Alvaro</td>
<td>Department of Clinical Biochemistry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain</td>
<td></td>
</tr>
<tr>
<td>Gastaldi Matteo</td>
<td>Neuroimmunology laboratory, IRCCS Mondino Foundation</td>
<td></td>
</tr>
<tr>
<td>Gerhards Catharina</td>
<td>Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Theodor Kutzer Ufer 1-3, 68167 Mannheim, Germany</td>
<td></td>
</tr>
<tr>
<td>Gillery Philippe</td>
<td>University Hospital of Reims, France</td>
<td></td>
</tr>
<tr>
<td>Gouget Bernard</td>
<td>IFCC-COFRAC-Ministry of Health</td>
<td></td>
</tr>
<tr>
<td>Grieve Graham</td>
<td>HL7 FHIR Product Director, Melbourne, Australia</td>
<td></td>
</tr>
</tbody>
</table>
QUALITY CONTROL
Leading provider of complete quality control solutions including: daily quality control, calibration verification and proficiency testing for results you can trust.

MOLECULAR DIAGNOSTICS
Molecular diagnostic solutions for clinical laboratory and POC settings. Our comprehensive test menu comprises infectious diseases including COVID-19, inherited diseases, mutation analysis and SNP genotyping.

CLINICAL CHEMISTRY ANALYZERS
Versatile range of biochemistry analyzers to suit all laboratory throughputs. Our world leading test menu delivers unrivalled consolidation and cost savings.

OPEN CHANNEL REAGENTS
The most extensive range of open channel biochemistry reagents facilitating routine and niche diagnostic testing.

TOXICOLOGY
Dedicated to advancing forensic, clinical and workplace toxicology globally; minimising laboratory workflow constraints whilst maximising the scope of quality drug detection.

Visit store.randox.com to buy directly from Randox today
randox.com marketing@randox.com

Product availability may vary from country to country. Some products may be for Research use Only. For more information on product application and availability, please contact your local Randox representative.
Gruson Damien  Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
Gul Ayse Zehra  Bezmialem Vakif University, Turkey
Günter Ulrich  University of Lübeck - Institute of Chemistry and Metabolomics, Germany
Haselmann Verena  Institute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Germany
Hofmann Walter  SYNLAB MVZ humane Genetik München, Zweigniederlassung der SYNLAB MVZ Augsburg GmbH, Ausgelagerte Praxisräume Dachau, Germany
Horvath Andrea Rita  NSW Health Pathology, Department of Chemical Pathology, Sydney, Australia
Ichihara Kiyoshi  Yamaguchi University Graduate School of Medicine, Faculty of Health Sciences, Ube, Japan
Ijzerman Maarten  University of Melbourne Centre for Cancer Research, University of Melbourne, Parkville, Australia
Jacobs Ellis  Ej Clinical Consulting, LLC, USA
John Garry  Department of Clinical Biochemistry and Immunology, Norfolk and Norwich University Hospital, UK
Joos Simon A.  Department of Tumor Biology, 2Mildred Scheel Cancer Career Center HaTricCS4, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany
Katsaros Sergios  Science and Technology Park of Crete, Heraklion, Greece
Keller Andreas  Clinical Bioinformatics, Saarland University, Saarbrücken, Germany
Khan Adil  Temple University, Philadelphia, USA
Kilpatrick Eric  Department Of Clinical Biochemistry, Manchester Royal Infirmary, Manchester, UK
Kitchen Steve  Sheffield Haemophilia and Thrombosis Centre, UK
Kittel Maximilian  Institute for Clinical Chemistry, Medical Faculty Mannheim, University of Heidelberg, Germany
Klouche Mariam  Medizinisches Versorgungszentrum Bremen, Germany
Koch Dave  Director, Clinical Chemistry, Toxicology, and POCT, Grady Memorial Hospital, Atlanta, USA
Kouri Timo  University of Helsinki, Department of Clinical Chemistry; and the EFLM Task and finish Group Urinalysis, Finland
Kourogiakiaouri Despoina  Science and Technology Park of Crete, Heraklion, Greece
Krischak Katharina  European Institute for Biomedical Imaging Research (EIBIR)
Lackner Karl  University Medical Center Mainz, Germany
Lammle Bernhard  Center of Thrombosis and Hemostasis, University Medical center Mainz, Switzerland
Langlois Michel  Dept. Laboratory Medicine, AZ St.Jan Hospital Bruges, Belgium
Lehmam Sylvain  Montpellier University Hospital, France
Lenski Marie  Univ. Lille, CHU Lille, Institut Pasteur de Lille, France
Leslie David  Blizard Institute, University of London, UK
Lianidou Evi  Analysis of Circulating Tumor Cells Lab, Department of Chemistry, National and Kapodistrian University of Athens, Greece
Lippi Giuseppe  University of Verona, Italy
Loh Tze Ping  Department of Laboratory Medicine, National University Hospital, Singapore
Luppa Peter  Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar der Technischen Universität München, Germany
Macq Benoit  UCLouvain, Belgium
Makris Konstantinos  Clinical Biochemist, Clinical Biochemistry, Department, Kat General Hospital, Athens, Greece
Mambet Christina  Carol Davila” University Of Medicine And Pharmacy, “Stefan S Nicolau” Institute Of Virology, Bucharest, Romania
Mariat Christophe  Service de Néphrologie, Dialyse et Transplantation rénale, Hôpital NORD, Université Jean Monnet, Saint-Etienne, France
Masnufa Intan Wibawanti  Prodia Lab, Indonesia
Matricardi Paolo Maria  Charité Universitätsmedizin Berlin – Dept of Pediatrics, Berlin, Germany
Meijer Piet  EQALM Board member / Chair EQALM Scientific Committee, The Netherlands
Monaghan Phillip  The Christie Pathology Partnership, Manchester, UK
Müller-Calleja Nadine  Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Mainz, Germany
Nauck Matthias  University Medicine Greifswald Institute of Clinical Chemistry and Laboratory Medicine
Neumaier Michael  Past President European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)
Nichols James H.  Vanderbilt University Medical Center, Nashville, USA
Niespodziana Katarzyna  Medical University of Vienna, Austria
Nordestgaard Borge  Dept. Clinical Biochemistry, Copenhagen University Hospital, University of Copenhagen, Denmark
Nordestgaard Borge  Dept. Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark
Ostermann Marlies  Guy's & St Thomas' Hospital London
Ozarda Yesim  Department of Medical Biochemistry, Istanbul Health and Technology University School of Medicine, Turkey
Paiva Bruno  Clinica Universidad de Navarra, Pamplona, Spain
Palladini Giovanni  University of Pavia and Foundation IRCCS Policlinico San Matteo, Italy
Petersmann Astrid  Zentrum für Laboratoriumsdiagnostik, Oldenburg, Germany
Phillips John  University of Utah School of Medicine, Division of Hematology, USA
Pillay Tahir  University of Pretoria & National Health Laboratory Service, Pretoria, South Africa
CONGRESS VENUE

ICM Internationales Congress Center München
MESSE MÜNCHEN GMBH
Messegelände
81823 München

An attractive venue

Munich is situated in the middle of Europe and a convenient destination for guests from home and abroad.

The attractive location on the Isar River, the proximity of the Bavarian Alps and the high quality of life make Munich a popular trade show and convention destination.

The ICM – Internationales Congress Center München is ideally located to offer participants a variety of culinary and cultural highlights in the Bavarian capital.

Excellent hotels and accommodations close to the event venue make guests’ stay at the Munich convention destination perfect.
**HOW TO REACH THE CONGRESS VENUE**

**By car**

Motorway A94 (München-Passau), exit “Feldkirchen”
Depending on your navigation system, you will find the Messe München either in the category “exhibition centre”, “trade fair centre” or under the German keyword “Messe”.

There is a parking closed to the congress centre
“Multi storey Parking Garage West”
Paul-Henri-Spaak-Str. 6 - 81829 Munich

**Costs:** 15,00 per day

**By plane**

From the airport, you can reach ICM comfortably by taxi or by public transport.
In this case, please take the suburban train line S8 (S-Bahn) to the stop “Ostbahnhof”. Then transfer to the underground line U5 (U-Bahn) direction “Neuperlach Süd” and get off at the station “Innsbrucker Ring”. Finally, transfer to the underground line U2 (U-Bahn) and stop at the station “Messestadt Ost”.

**By train**

From Munich’s Central Station (Hauptbahnhof), you will easily reach the ICM with the underground line U2 (U-Bahn). Please stop at the station “Messestadt Ost”.

---

**Diagram Description**

- Motorway A94 (München-Passau), exit “Feldkirchen”
- Depending on navigation, Messe München is found in exhibition centre, trade fair centre, or “Messe”.
- Multi storey Parking Garage West:
  - Paul-Henri-Spaak-Str. 6 - 81829 Munich
- From airport, take S8 (S-Bahn) to Ostbahnhof, then U5 (U-Bahn) to Neuperlach Süd, transfer to U2 (U-Bahn) to Messestadt Ost.
- From Central Station (Hauptbahnhof), take U2 (U-Bahn) to Messestadt Ost.
GENERAL INFORMATION

Registration Desk
The registration desk for the congress, located at the entrance of the Congress Center, Level 0, is open as follows:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 April</td>
<td>11:00 - 19:00</td>
</tr>
<tr>
<td>11 April</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>12 April</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>13 April</td>
<td>08:00 - 18:00</td>
</tr>
<tr>
<td>14 April</td>
<td>08:30 - 14:00</td>
</tr>
</tbody>
</table>

Official Language
The official language of the congress is English. No simultaneous translation is provided.

Name Badge
All participants will receive a name badge when they check-in at the registration desk. The badge must be worn at all times because only registered participants will be admitted to the scientific sessions. It must also be worn at the social events organised as part of the congress.

Munich Travel Card
A Munich public transportation pass, within the zone M (= complete Munich city area including Munich trade fair/ICM), is printed on the congress badge of all properly registered delegates. The pass entitles to an unlimited number of journeys with the MVV (S-/U-Bahn, tram and bus) for the duration of the congress, from 10 to 14 April 2022.

Congress Kit
The congress kit can be collected at the Bag Delivery Desk at Level 1, upon presentation of the congress-kit ticket provided with your badge.

Cloakroom
Cloakroom is available at Level Mezzanine of the congress venue. Delegates’ belongings (such as coats, bags, posters, etc.) can be left ONLY on a daily basis and ONLY during the congress's hours. In the end of each day, all left items will be given to security.

Business Centre
A business centre is available at Level 0 from Monday 11 April to Thursday 14 April, from 08:00 to 17:00.

AV Centre
The AV centre is located in Room 2, on Level 0. Speakers are kindly requested to bring their presentation to the audiovisual centre on a USB drive at least two hours before the presentation is scheduled. Personal laptops cannot be connected to the system.

Certificate of Attendance
All properly registered attendees will receive a certificate of attendance via e-mail, the week after the congress.
Wireless Connection
Euromedlab Munich 2021 is offering free WiFi for delegates in all Congress Center. Network: euromedlab2021

Posters
Posters are displayed inside the Exhibition Area, Hall C1, of the Congress Centre. Posters are arranged by topic and displayed on three different days:

<table>
<thead>
<tr>
<th>Monday, 11 April</th>
<th>Tuesday, 12 April</th>
<th>Wednesday, 13 April</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-17:30</td>
<td>10:00-17:30</td>
<td>10:00-17:30</td>
</tr>
</tbody>
</table>

Posters are numbered and must be on display on the day that the Organising Secretariat assigned the authors, according to the following schedule only:

- set-up 09:30-10:00
- removal 17:30-18:00

Posters differ by topic every day and the Organising Secretariat declines any responsibility for posters left on display afterwards.

In order to encourage discussions about posters, the poster Presenter must be at the assigned poster panel from 13:00 to 14:00.

Abstract Publication
All abstracts are published in a special on-line issue of Clinical Chemistry and Laboratory Medicine (CCLM).

Industry Exhibition
The exhibit of diagnostics companies make up a very important part of the congress. All major international and German clinical-biochemistry and laboratory-medicine companies are represented.

Participants are encouraged to visit the large industry exhibition, which is located in Hall C1 and open as follows:

<table>
<thead>
<tr>
<th>Monday, 11 April</th>
<th>Tuesday, 12 April</th>
<th>Wednesday, 13 April</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:00-17:30</td>
<td>10:00-17:30</td>
<td>10:00-17:30</td>
</tr>
</tbody>
</table>

Access to the exhibition area is free of charge and does not require congress registration. However, for security reasons, anyone wishing to visit the exhibition without registering for the congress must report to the Visitors Desk at the entrance of the Congress Centre, Level 0.

For those who cannot participate, we have designed a brand-new format of interacting with the companies during this conference: the “Exhibition Floor Walks”. The links for the Zoom Connection are available on the congress website.

Coffee Points
During intermission in the morning, inside the exhibition area, self-service coffee points offer coffee and tea free of charge for all properly registered delegates.

Bar/Restaurant
A cash bar will be operating during the congress. It is located in the exhibition area, open on Monday, Tuesday and Wednesday from 10:00 to 17:30.
The Healthcare Landscape is Evolving. Are You?
Because Every Step and Every Aspect of Your Laboratory Impacts Patient Care.

Ortho Highlights at EUROMEDLAB

VITROS® Dashboards
Web based system designed to provide productivity information regarding analysers, test volumes, workload balance, HIT levels, and reagent efficiency.

Optimizing Patient Blood Management
The role of the laboratory in managing common interferences and how to reduce impact in patient results.

Assay Menu
Our broad menu of high-performing assays are optimized to meet your changing testing needs.

Ortho’s Educational Workshops

EDUW 15 – ROOM 1 - Tuesday, April 12, 14:00-15:00 CET
Chimeric Antigen Receptor (CAR)-T cell therapy: research findings, clinical applications, and markers to control cytokine release syndrome - How can laboratory tests contribute to a favorable patient outcome? Which biomarkers are currently of interest to assess cytokine release syndrome and neurotoxicity associated with CAR-T cell therapy?

Chairman /Scientific coordinator:
- Els Melis - Senior Manager EMEA Clinical Labs Assays - Ortho Clinical Diagnostics

Speakers:
- Prof. Álvaro Urbano Ispizua - Director of the Institute of Hematology and Oncology - Hospital Clinic Barcelona and Full Professor of Medicine at the University of Barcelona.
- Cecilia Scarponi - EMEA Clinical Liaison - Ortho Clinical Diagnostics

EDUW 29 – ROOM 1 - Wednesday, April 13, 14:00-15:00 CET
Sustainable Laboratory Medicine: Prepare for the future now!
In the coming years, the impact of sustainability will be increasingly felt in healthcare. Evolution of regulation will impose changes on technology used and in environmental mitigation costs. Altogether, sustainability is set to shape the future direction of hospitals and laboratories.

Chairman /Scientific coordinator:
Dr. Bernard Gouget, Ph.D – ex-Assistant Professor at the University Hospital in Paris Descartes. President-Healthcare Division Executive Committee, Comité Français d’accréditation (Cofrac) President, National Committee for the selection of Reference Laboratories, Ministry of Health

Speakers:
- Prof. Damien Gruson - Head of the department of Laboratory Medicine of the Cliniques Universitaires Saint Luc – Brussels, Belgium
- Jordi Trafí-Prats - Senior Director EMEA Marketing - Ortho Clinical Diagnostics

Be part of the evolution. Visit us at Hospitality Room #12a
www.orthoclinicaldiagnostics.com
MC-80
Automated Digital Cell Morphology Analyzer


Mindray’s revolutionary MC-80 automated digital cell morphology analyzer can provide more clarity, more intelligence and more productivity for morphological analysis. It takes digital morphology analysis to the next level, delivering clearer images which are able to capture abnormalities in more detail. With advanced algorithms, the analyzer enables better identification of different cells with high throughput, resulting in greater productivity. With the newly launched MC-80, Mindray now can provide total solution for hematology analysis which can assist pathologists in quicker and more accurate diagnoses.

www.mindray.com
**REGISTRATION**

Full registration and young registration fees include:

- entrance to plenary lectures, symposia, educational workshops, poster area and exhibition
- a free app containing the Scientific Programme with the Abstracts and the slides of the presentations, and the Abstracts of the posters
- certificate of attendance
- Munich travel card
- coffee and tea service during morning intermissions
- Opening Ceremony (Sunday, 10 April 2022)
- Closing Ceremony (Thursday, 14 April 2022)

The day registration fee includes, for the day of registration only:

- entrance to plenary lectures, symposia, educational workshops, poster area and exhibition
- a free app containing the Scientific Programme with the Abstracts and the slides of the presentations, and the Abstracts of the posters
- certificate of attendance
- coffee and tea service during morning intermissions

**On-site Registration Fees**
*(vat included)*

<table>
<thead>
<tr>
<th>Registration</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>FULL REGISTRATION</td>
<td>€900</td>
</tr>
<tr>
<td>YOUNG REGISTRATION</td>
<td>€480</td>
</tr>
<tr>
<td>DAY REGISTRATION</td>
<td>€420</td>
</tr>
</tbody>
</table>

Delegates can pay registration fees in euros only; cash or credit card (American Express, MasterCard, Visa) accepted.

**Liability and insurance**

Registration fees do not include the insurance of participants against personal accidents, sickness and cancellations by any party, theft, loss or damage to personal possessions.
Welcome to the age of Microfluidics

Next generation microfluidic technology on the LumiraDx Platform enables lab-comparable performance across a broad menu of assays designed to transform community care.

- Rapid actionable results
- Consolidates POC analyzers
- Lab-comparable performance
- One integrated Platform

SARS-CoV-2 Neutralisation Assays

SARS-CoV-2 IgG (RBD & NP)

- Rapid turnaround time of 1.5 hours to results
- Medium to high throughput (Capable of processing 54 patient samples simultaneously)
- Batch testing
- Limited sample volume requirements
- Comprehensive immunoassay and molecular test menu

lumiradx.com

Copyright © 2021 LumiraDx UK LTD. All rights reserved worldwide. LumiraDx and FLume logos are protected trademarks of LumiraDx International LTD. Full detail of these and other registrations of lumiradx can be found at lumiradx.com. All other trademarks are the property of their respective owners. Product not available in all countries and regions.
SARS-CoV-2 Neutralisation Assays

• Detect antibodies that block interaction of RBD and ACE2
• Identify immune response to both Wuhan and Delta variants
• Measure vaccine efficacy and estimate herd immunity
• Determine longevity of immune response to post vaccine infection
• Establish eligibility for a booster vaccination
• Detect antibodies that are capable of inhibiting virus replication and neutralising the infectivity of SARS-CoV-2
• Specificity of 100% and sensitivity of 98% compared to conventional virus neutralisation tests

SARS-CoV-2 IgG (RBD & NP) Array

• Uniquely measuring antibodies reactive to both RBD and NP
• Distinguish vaccinated from naturally infected individuals
• Compatible with capillary and venous blood collection
• Identify incidence of SARS-CoV-2 infection in vaccinated individuals
• Specificity of 99.5% and sensitivity of 100% ≥ 10 days post SARS-CoV-2 PCR confirmation

EVIDENCE INVESTIGATOR
Semi-Automated Analyser

- Rapid turnaround time of 1.5 hours to results
- Medium to high throughput (Capable of processing 54 patient samples simultaneously)
- Batch testing
- Limited sample volume requirements
- Comprehensive immunoassay and molecular test menu

marketing@randox.com
randox.com
Come and visit us
at Hall C1 Booth #28
10-14 April 2022

Explore the future

HORIBA Medical is committed
to providing the right solution,
adapted to your precise requirements.

Now there is no more compromise,
just one solution ... yours!

Exceeding expectations in hematology & hemostasis analysis!
For information on any specific topic, please refer to the following e-mails:

General information: info@euromedlab2021munich.org
Abstracts & Posters (info only): posters@euromedlab2021munich.org
Companies: companies@euromedlab2021munich.org
Registrations: registrations@euromedlab2021munich.org
Hotel reservation: isapir@kenes.com Attn: Mrs. Irina Sapir

ABBOTT
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our solutions are used in healthcare institutions, physician offices, emergency rooms and laboratories thousands of times every day, in practically every country around the world. Our test results are often the “start” button for patient care decision-making – influencing 70% of critical healthcare decisions for millions of people worldwide. The crucial information derived from our testing platforms helps inform treatment decisions for hundreds of health conditions from heart attacks to blood disorders to infectious diseases and cancers.
Learn more about Abbott on our website ("website" to be hyperlinked to https://www.corelaboratory.abbott/int/en/home)
Address:    Contact:
Abbott GmbH    wired@abbott.com
Max-Planck-Ring 2   Tel.: 49 6122 583
65205 Wiesbaden, Germany

ROCHE
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche Diagnostics International Ltd.
Centralised and Point of Care Solutions
Forrenstrasse 2
6343 Rotkreuz, Switzerland
www.roche-rotkreuz.com

SIEMENS HEALTHINEERS
Siemens Healthineers AG (listed in Frankfurt, Germany; SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
GOLD SPONSORS

RANDOX
Randox is committed to improving health worldwide with the firm belief that the healthcare of tomorrow depends on innovations developed today. Our passion for innovation, creativity and investment in R&D enables us to continually develop our products and evolve for the future. As a world leader in the in-vitro diagnostics industry, Randox is committed to developing revolutionary diagnostic products designed to improve health globally including chemistry, immunoassay, molecular & POC analysers in addition to high quality reagents. Leading provider of complete quality control solutions including; daily quality control, calibration verification and proficiency testing for results you can trust. Biochip Array Technology is a unique multiplexing method offering clinical, research and molecular panels. We also offer a range of COVID-19 testing solutions for all testing needs. Randox is leading the change in moving from a one-size-fits-all approach towards decisions and products tailored to the needs of the individual.

SNIBE
Shenzhen New Industries Biomedical Engineering Co., Ltd (briefed as Snibe) is a leading global in-vitro diagnostic biomedical company. Snibe has focused on the Chemiluminescent immunoassay (CLIA) field for more than 26 years. We are providing customized diagnostic solutions to laboratories in more than 146 countries and regions. Over 18000 units of Snibe's products have been installed in hospitals and labs worldwide, including global chain labs like Synlab, Eurofins, Cerba, Synevo, etc.
Snibe established 4 core R&D centers, including reagent, instrument, magnetic microbead, and reagent raw material to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. We successfully developed the fastest CLIA analyzer in the world - MAGLUMI X8 with the throughput of 600T/H in 2018. In order to meet the demand of mega-laboratories, Snibe announced a strategic partnership with Thermofisher and Hitachi to launch the Total Laboratory Automation solution in 2019. Moreover, to help the fight against COVID-19, Snibe successfully developed the 2019-nCoV (SARS-CoV-2) CLIA Kits in 2020, the first of its kind in the world to received CE mark.
Our Mission is "Creating value for human health through continuous innovation".
Address     Contact
No.23, Jinxiu East Road,  sales@snibe.com
Pingshan District      Tel.: +86-755-86540750-8681
518122 Shenzhen, P.R. China www.snibe.com

SYSMEX
Sysmex supports healthcare professionals around the world in lighting the way with diagnostics by providing a broad range of medical diagnostics products and solutions. In the fields of haematology, urinalysis, haemostasis, life science, flow cytometry, essential healthcare and now immunochemistry, we combine highly dependable, multi-functional and easy-to-operate instruments, a variety of reagents and software, plus reliable service and support.
Sysmex Europe GmbH, located near Hamburg, Germany, is a subsidiary of the Sysmex Corporation from Kobe, Japan. From our Hamburg offices, we serve our affiliates, distributors and customers throughout Europe, the Middle East, and Africa (EMEA).
For more information, visit www.sysmex-europe.com.
Sysemex Europe GmbH     Contact
Bornbarch 1             Tel.: +49 (40) 527 26 0
22848 Norderstedt, Germany Fax.: +49 (40) 527 26 100
www.sysmex-europe.com    E-Mail: info@sysmex-europe.com
MINDRAY
At Mindray we believe each test you do is important, because each patient is important. As the majority of healthcare decisions are based on laboratory tests, it’s more critical than ever that you are able to trust your results.

Mindray empowers this trust through technology, innovation, and our commitment to the advancement of in-vitro diagnostics science. Mindray has developed reliable and robust solutions to empower trust, delivering accurate results while meeting increasing demands on efficiency in laboratories worldwide.

ORTHO CLINICAL DIAGNOSTICS
Ortho Clinical Diagnostics (Nasdaq: OCDX) is a leading global provider of in vitro diagnostics. We have an established track record for providing high-quality products and services to the global clinical laboratory and immunohematology communities.

We provide hospitals, hospital networks, clinical laboratories and blood banks around the world with innovative technology and tools to ensure test results are fast, accurate and reliable. Our customized solutions enhance clinical outcomes, improve efficiency, overcome lab staffing challenges and reduce costs. Because Every Test Is A Life.™

Website: In Vitro Diagnostics Solutions | Ortho Clinical Diagnostics
Contact: Sandra Ferreira - sandra.ferreira@orthoclinicaldiagnostics.com

SEBIA
Our mission is to provide powerful tools that translate what is happening in a patients’ body into a readable and interpretable language.

We call it our new language of life. It makes it easier to understand, diagnose and treat chronic and metabolic diseases. Cancer, obesity, aging and depression share a common biology: they are metabolic and inflammatory. Those pathological imbalances lead to protein modification which require special separation techniques to give us a better understanding. Capillary Electrophoresis (CE) is the most accurate and efficient method of separation to unlock these complex conditions.

Sebia is the world’s leading provider of clinical protein electrophoresis equipment and reagents for the screening and monitoring of various diseases, primarily in the areas of Oncology (Multiple Myeloma), Diabetes, Hemoglobinopathy and other rare pathologies. The company is headquartered in France and is present in more than 120 countries.

Address: 27 rue Léonard de Vinci
91090 Lisses, FRANCE
Contact: Tel.:+33 (0) 1 69 89 80 80
www.sebia.com

THE BINDING SITE
Binding Site provides specialist diagnostic products to clinicians & laboratory professionals worldwide. Delivering innovative medical solutions that improve the diagnosis and management of blood cancers & immune system disorders. We are committed to improving patient lives worldwide through education, collaboration, and innovation. Visit us on stand 18 and see how we can help you to maximise your protein service.

Discover our dedicated special protein system Optilite®, the latest innovation in special protein analysis, delivering, fast, high-quality, and reliable results at an impressive throughput.

Learn how Myeloma patients benefit from Freelite® assays, Freelite® is the ONLY serum free light chain test recommended by International and national guidelines with more than 20 years of clinical evidence.

Address: 8 Calthorpe Road,
Birmingham B15 1QT
Contact: Tel.:+44 (0) 121 456 9500
info@bindingsite.com
www.bindingsite.com
BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help improve patient outcomes, improve the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to better diagnose disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. www.bd.com

DIASORIN
World leaders in the lab diagnostics market, we are specialists in the immunodiagnostics and molecular diagnostics segments and active in the Licensed Technology sector. The Company has been developing, producing and marketing reagent kits for laboratory diagnostics all over the world, for over 50 years. The extensive diagnostic testing and Life Science offer, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the “Diagnostic Specialist”. Our tests enable delivery of reliable - early diagnosis of various pathologies for millions of people who will then be able to receive the most appropriate therapy. Our Licensed Technology sector offers technological solutions based on the platforms and reagents required by academic, pharmaceutical and industrial diagnostics research for the development and production of health goods. www.diasoringroup.com www.diasorin.com - www.molecular.diasorin.com - www.luminexcorp.com
Address
DiaSorin S.p.A. Luminex DIASORIN MOLECULAR LLC
+39 0161 487.1 +1 512 219 8020 +1.562.240.6500
Via Crescentino Snc 12212 Technology Blvd 11331 Valley View St.,
13040 Saluggia (VC) Suite 130 - Austin, TX 78727 Cypress, CA 90630

ELITECHGROUP
ELITechGroup, founded in 1997, is a privately held group of worldwide manufacturers and distributors of in-vitro diagnostic equipment and reagents. By bringing together IVD specialty companies that offer innovative products and solutions, ELITechGroup has become a major contributor to advancing clinical diagnostics across a range of laboratory disciplines: clinical chemistry, microbiology, hematology and molecular diagnostics. ELITechGroup Clinical Systems sets the standard in benchtop Clinical Chemistry with fully integrated, state of the art clinical chemistry systems and superior test menu of liquid-stable, ready-to-use reagents. ELITechGroup Molecular Diagnostics provides innovative molecular diagnostics solutions for a wide range of diseases including a leading proprietary MGB Probe technology. ELITechGroup Biomedical Systems specializes in comprehensive range of slide stainers and osmometers recognized worldwide for proven performance and reliability. ELITechGroup Microbiology provides diagnostic kits for the identification, enumeration and susceptibility testing of infectious diseases.
HORIBA MEDICAL
HORIBA Medical provides an extensive and comprehensive line of hematology, hemostasis, clinical chemistry and automation solutions (including analyzers, reagents and consumables) for use in in vitro diagnostics. Proven quality and trustworthy performance have established widespread confidence in the HORIBA Medical brand. Today, more than 30,000 laboratories are using HORIBA Medical's devices around the world. This year, we will specially showcase our automation high-end HELO* Solution (HORIBA Evolutive Laboratory Organisation) as well as our Yumizen range of hemostasis analyzers for small to large size laboratories and a COVID-19 corner. Come and visit us at HORIBA Medical booth #28 during EuroMedLab. Join us on our social media (linkedin, facebook and twitter) to share and “like” our latest news!

STAGO
With a staff close to 2,500 and the most advanced technologies, Stago formulates, manufactures and markets worldwide, the broadest range of reagents and analytical instruments in hemostasis. Stago devotes its research and innovative skills to the development of increasingly effective medical diagnostic products and instrumentation. Because we are committed to a better understanding of hemostasis and thrombosis, Stago’s creativity, supported by a team of specialized researchers, results in a range of reagents and instruments which just keeps getting better. This involves constant leading-edge research as well as the improvement of existing kits. Thanks to a wide international network of distributors and affiliates, Stago is represented in more than 110 countries. Without exception, each distributor is chosen according to strict criteria regarding the performance of its team, its capabilities in after-sales services, and its commitment to knowing and promoting the Stago line.

THERMO FISHER SCIENTIFIC
Thermo Fisher Scientific is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner, and safer. Through our Thermo Scientific™, Applied Biosystems™, Invitrogen™, Fisher Scientific™, and Ion Torrent™ brands, we help customers accelerate innovation and enhance productivity. Collaborate with our team to discover more ways to solve your toughest challenges. Our teams bring together key focus areas to help you, our heroes, with your daily lab work or research projects. Learn more about the applications, tools and technologies spanning from diagnostics development, a therapeutic drug monitoring and drug screening, and the latest mass spectrometry equipment. See our broad range of laboratory equipment and supplies for every size lab.

Address:      Contact
46500 Kato Road      www.thermofisher.com
Fremont, CA 94538      Visit us at Booth # 247
(510) 979-5000
Twitter:  https://twitter.com/thermofisher
Facebook: https://www.facebook.com/thermofisher
Linkedin: https://www.linkedin.com/company/thermo-fisher-scientific/

WERFEN
Werfen is a growing, family-owned, innovative company founded in 1966 in Barcelona, Spain. We are a worldwide leader in specialized diagnostics in the areas of Hemostasis, Acute Care Diagnostics and Autoimmunity. Through our Original Equipment Manufacturing (OEM) business line, we research, develop and manufacture customized assays and biomaterials. Our mission is to improve the quality of laboratory medicine worldwide. At present, we operate directly in nearly 30 countries and in more than 100 territories through distributors. Our headquarters and technology centers are located in Europe and the United States. In 2021, our revenues were € 1.854 billion and our workforce is 5,794 strong.

Address:      Contact
Werfen      www.werfen.com
Plaza de Europa nº 21-23
08908 L’Hospitalet de Llobregat
Barcelona, Spain
Faecal metagenomic analysis at the medical lab to empower clinical diagnosis & management

Meet us at BOOTH 181
A.MENARINI DIAGNOSTICS
A. Menarini Diagnostics, the Human Touch of Technology: more than 45 years dedicated to helping healthcare professionals make safe and sustainable diagnosis, improving the quality of life of people all over the world. A. Menarini Diagnostics is committed to bringing innovative solutions in the In Vitro Diagnostics market and to the development of high-tech diagnostics systems and reagents to improve patients’ quality of life, providing healthcare professionals with the best possible solutions for their diagnostics needs. With extensive investments in research, strategic alliances and presence in the healthcare community, Menarini’s efforts are in two main areas: Laboratory Products, including the new pre-analytical management of samples from check-in to the specific lab analyser, a range of systems for glycated haemoglobin, urinalysis, point of care solutions and autoimmunity and infectious diseases routines to meet the needs of core and specialties laboratories. Diabetes Care Products, with the most comprehensive portfolio of glucose monitoring solutions.

ARK DIAGNOSTICS
ARK Diagnostics Inc. develops, manufactures, and distributes in vitro diagnostic immunoassays for Therapeutic Drug Monitoring (TDM) and Urine Drug Testing (UDT). For TDM, clinicians use these measurements to guide dosing decisions for safe, effective, and personalized drug therapy. By optimizing drug levels, clinicians improve outcomes, reduce toxicity, and lower healthcare costs. For UDT, ARK has several unique assays for Fentanyl II, Pregabalin II, Gabapentin, and Methylphenidate Metabolite. Additionally, ARK has many other unique TDM and UDT Assays. ARK’s quality management system is certified to ISO 13485:2003. The company is committed to quality compliance and carefully follows Good Manufacturing Practices. ARK uses its unique blend of scientific expertise and deep industry knowledge to deliver high-quality assays for new generations of drugs. Its highly regarded homogeneous enzyme immunoassay technology is adaptable to a variety of clinical chemistry analyzers.

BIO-RAD LABORATORIES
Founded in 1952, Bio-Rad Laboratories is a world-leading provider of products for the life science research and clinical diagnostic markets. Our mission is to advance discovery and improve lives. Our Clinical Diagnostics Group provides innovative in vitro diagnostics solutions that allow clinicians to diagnose, monitor and treat diseases and other medical conditions. These include diabetes monitoring, blood virus testing, blood typing, autoimmune, microbiology, genetic disorders and quality control systems. With over 300 clinical diagnostic tests available, we are renowned for our commitment to quality and customer service in hospital, reference and transfusion laboratories as well as universities, research institutions, biotechnology and pharmaceutical companies.

BÜHLMANN
BÜHLMANN is the established provider for excellence in reliable quantitative fecal analysis of calprotectin and pancreatic elastase. The clinical value is proven in over 100 peer reviewed publications. The BÜHLMANN fCAL® turbo assay is the consequent continuation of this success and is applicable on most clinical chemistry platforms allowing random access and fulfills today’s requirements for automation and streamlining of the workflow in a modern lab environment. The unique CALEX® stool extraction device provides the quality needed for quantitative fecal analysis; its ease of use eliminates direct contact with stool. The design and the consequent separation of pre-analytics and analytics allows lay persons to collect the sample and lab staff only needs loading the sample onto laboratory tracking systems. BÜHLMANN also offers rapid and easy lateral flow analysis in inflammatory diseases with Quantum Blue® calprotectin, infliximab and adalimumab testing for immediate therapy adaptation options. The Exhibiting COMPANY’s main areas of activity are:

ASP LAB AUTOMATION
ASP Lab Automation is your partner for the efficient design of sample receipt in medical laboratories. We offer automation solutions for sample preparation and postanalytical processing. We advise our customers on improving their processes. We are a dynamic company with experienced, highly motivated employees who work closely together in a modern corporate culture with flat structures. Our goal is to deliver robust, reliable, and easy-to-use solutions to the constantly growing market requirements of medical laboratories worldwide. What sets us apart. A deep understanding of the client’s needs and our commitment to problem solving with a solution-oriented drive are a strong foundation to our innovation style. To that, we add the hard work of a special team with a rare skillset of knowledge and passion for better, faster, modern technology that sets new standards.

BÜHLMANN Laboratories AG
Baselstrasse 55, CH-4124 Schönenbuch
Phone +41 61 487 12 12 - Fax +41 61 487 12 34
info@buhlmannlabs.ch · www.buhlmannlabs.ch
Gentian is a Norwegian diagnostics company that develops and supplies assays for clinically relevant biomarkers available on high-throughput clinical chemistry platforms, utilising the Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology. Our current portfolio and future pipeline of diagnostic reagents span diverse areas like kidney disease, cardiac disease, inflammation, infection and veterinary medicine.

Assays for highly relevant biomarkers for a wide range of clinical chemistry platforms

- GCAL® - Plasma and serum calprotectin
- Cystatin C
- Canine CRP
- SARS-CoV-2 Total Antibody - Launch 2022

On instruments already in your laboratory

We supply our reagents to both clinical laboratories and instrument providers. Our aim is to have our products available for use on all major clinical chemistry platforms currently on the market.

In addition, we plan to bring a new assay to the market every year. Please let us know if you are interested in collaboration.
BYG4LAB®
BYG4lab® is the largest European company specialized in Middleware and Data Management solutions in the field of medical biology. Our organisation gives us all the agility we need to better support our customers and partners in their challenges, in a constantly changing environment. BYG4lab® covers all disciplines, all instruments and all organizations.
BYG4lab®
13 Rue d’Ariane, 31240 L’Union
1 Allée de Saint Cloud 54600 Villers les Nancy
Tel : 05 34 25 07 10
Website : www.byg4lab.com

COLLEGE OF AMERICAN PATHOLOGISTS
As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and external quality assessment/proficiency testing (EQA/PT) programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP’s EQA/PT program offers a comprehensive range of programs that constantly evolve to keep laboratories in step with these changes to have more time for what matters most—accuracy in the laboratory. From routine to esoteric, our programs help laboratories deliver performance they can measure and accuracy they can trust. For more information on our EQA/PT, visit cap.org. Also, learn more about the CAP: CAP Annual Report.
Oliver SchnaedeLbach
oschnae@cap.org
College of American Pathologists
325 Waukegan Road
Northfield, IL 60093 USA

COMED
Independent - Dynamic - Innovative
We provide global IT solutions for medical diagnostics providers and the IVD industry.
COMED is a leading provider in the development and implementation of state-of-the-art ERP, supply chain management and e-commerce solutions in healthcare. COMED also provides an innovative Lab platform for test orders and online result reporting connecting 100+ hospitals with more than a dozen reference labs.
Countries: 20 | Daily Users: 22,000
Realised Projects: 400 | Different Host Interfaces: 160
International Installation: 1,800
Daily Webshop Users: 1,300
Purchasing Volume: > 2 bn per year (material management solution)
• Multinational Lab Groups & Private Reference Labs
• University Hospital Labs
• Acute Hospitals
• Rehabilitation Clinics
• Ophthalmology, Ophthalmic Surgery & Diagnostic Centers
• Public Sector, Public Welfare, Education, Communities, Retirement Homes
• Agricultural, Environmental, Water, Food & Feed Laboratories

DIAGAM
DiAgam is a European company, with more than 25 years of experience, which manufactures Turbidimetric Specific Protein reagents.
Recognized as a very good quality assays, our leading innovative solutions are offered in user friendly instrument specific packaging for open chemistry systems from world leading instrument manufacturers including Abbott, Beckman, Siemens, Ortho Clinical Diagnostics or Roche®. These end-finished packaging kits save operator time and improve laboratory efficiency by eliminating reagent transfer. Our solutions are also available in OEM for any distributor which is looking for a high quality Specific Protein reagents menu. Our operations are ensured through our direct affiliates in Belgium, France, Spain, Portugal and Brazil. We also export in ASEAN, EMAE, LATAM and US markets. Our assets are:
• Very good correlation versus Nephelometry
• Liquid reagents, controls and calibrators (traceable to International Standards (WHO, IFCC, NIBSC...))
• Long expiration date and stability aboard instruments
• Registration and technical support with specialized staff
• Nanotechnologies with colloidal particles for CRP, Calprotectin, Cystatin C, Ferritin, RF and now with our innovative SARS-CoV-2 assay (a serological turbidimetric test for chemistry systems**)
Assays available:
Albumin (immunological), Albumin in CsF, Alpha-1-acid glycoprotein, Alpha-1-antitrypsin, Alpha-1-microglobulin, Alpha-2-macroglubulin, Beta-2-microglobulin, Apolipoprotein A1, Apolipoprotein B, ASO, Calprotectin, Complement C3, Complement C4, Cereuloplasmin, CRP, Haptoglobin, Ig A, Ig E, Ig G, Ig G in CsF, Ig M, Lipoprotein(a), Microalbumin, Prealbumin, Rheumatoid Factor, Retinol binding protein, SARS-CoV-2, Transferrin.
*All products names, registered trademarks, company names in this document remain the property of their respective owners
** For Research Use Only

DIASOURCE
DIAsource ImmunoAssays® SA (a Biovendor Group company), an international diagnostic company (based in Belgium), develops, manufactures and markets clinical diagnostic products in the field of endocrinology, autoimmunity and infectious diseases.
Core products are based on RIA and ELISA technology and also include reagents to be ran on open ELISA and RIA automated analyzers as well as antibodies for use in in-vitro diagnostic assays.
DIAsource has specific development and manufacturing programs for our Vitamin D panel, steroids and androgens and many others parameters. We also provide selected instrumentation: we offer ELISA reader, - washer and - shaker, along with open and closed fully automated ELISA and RIA platforms helping our customers to automate their tests. We also promote the CLIA system for modern, fast and reliable diagnostics.
It is our ambition to use our 35 years of expertise in Antibody - and Assay development to remain a well-known company of diagnostic immunoassays and instrumentation for the IVD market.
DIAsource ImmunoAssays® SA
rue du bosquet 2 - 1348 Louvain-la-Neuve, Belgium
peter.kerckx@diasource.be
DiaSys Diagnostic Systems began as a pioneer in the field of liquid-stable reagents in 1991 and has since become a well-established provider of diagnostic system solutions for small to medium sized laboratories. Dedicated to “Choosing Quality”, DiaSys’ priority is to provide high quality products and excellent service.

Focusing on clinical chemistry and immunoturbidimetric assays, DiaSys has introduced more than 90 optimized reagents for routine and special diagnostics in user-friendly kits for manual or automated use, as well as dedicated calibrators and controls. One of the latest innovations in the portfolio is a Procalcitonin assay for sepsis diagnosis, developed according to the PETIA test principle.

The instrument portfolio comprises fully automated clinical chemistry analyzers, semi-automated analyzers, POCT instruments and water purification systems. Thanks to this comprehensive range of reagents, analyzers and services, DiaSys, as a reliable partner, fulfills specific customer needs.

Contact details:
DiaSys
Diagnostic Systems GmbH
Alte Strasse 9
65558 Holzheim
Germany
Phone: +49 6432 9146-0
Email: info@diasys.de

DIESSE
DIESSE Diagnostica Senese SpA is an Italian company with integrated and entirely inhouse production of in vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems primarily in the field of immunodiagnostics and automatic measurement of erythrocyte sedimentation rate (ESR). The company has a global presence in over 100 countries, three production sites and a research centre where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, making DIESSE synonymous with “Diagnostics Evolution”.
Federica Casiraghi
federicaCasiraghi@diesse.it
Tel. +39 342 9511925
DIESSE Diagnostica Senese Spa
Via Strada dei Laghi 35-39, Z.I. Casone, Ingresso 6
Monteriggioni
53035 Siena, ITALY

DIRUI
DIRUI is headquartered in Changchun, northeastern industry base of China, a provider of high-quality in vitro diagnostic products for the global market.

Within 29 years of experience, DIRUI product portfolio is covering biochemistry, urinalysis, hematology, chemiluminescence immunoassay, gynecology, coagulation, molecular diagnostics, and standardized laboratory 8 product lines. We provide personalized laboratory solutions that can meet the diverse needs of customers. DIRUI diagnostic systems are served in hospitals, reference laboratories, and medical institutions in over 120 countries and regions. As an ISO 13485 and ISO 9001 certified manufacturer, DIRUI passed NGSP, RIQAS, and CAP external quality assessment program, all of DIRUI’s products are CE certified, some of which are holding FDA certification. Visit our booth (#109) to learn more or at www.dirui.com.cn/en.

Dirui
email: marketing@dirui.com.cn
Contact address: #3333 Yiju Road, High & Development Zone, Changchun City, China.

EDAN INSTRUMENTS
EDAN Instruments, INC. is a global high-tech company dedicated to providing innovative and high-quality medical devices, it has five product categories including Obstetrics & Gynecology, Patient Monitoring and Diagnostic ECG, to Ultrasonic Imaging Systems and In-Vitro Diagnostic. Edan subdivides IVD into POCT and laboratory diagnostics. In POCT line, Edan has the 1st Chinese ABG analyzer i15, which can provide more than 30 parameters results within minutes. m16, a portable immunoassay analyzer, has excellent accuracy and precision specifications that is comparable with those in central-labs. In IVD line, Edan-Messer Diagnostics* develops the compact 3 and 5 part differential hematology analyzer.

EXIAS MEDICAL
EXIAS Medical is a company located in Graz, Austria that is developing analyzers in the point-of-care and laboratory field since 2014. EXIAS is utilizing the long-term experience of its team in order to develop innovative technology to address the needs of healthcare professionals all over the world.

EXIAS Medical GmbH
Kratkystraße 2, 8020 Graz, Austria
Web: www.exias-medical.com
Email: office@exias-medical.com

FOSUN DIAGNOSTICS
Founded in 1989, Fosun Diagnostics (Shanghai) Co., Ltd. is a global provider of diagnostic technology innovation solutions. On May 18, 2021, “Fosun Diagnostics” completed the official renaming, set up six major R&D and production bases in China and continuously improved the integrated industrial layout of “diagnosis to treatment” for the R&D and manufacture of IVD instruments and reagents, and the products involved clinical chemistry, clinical immunity, molecular diagnosis, microbiology, POCT and other laboratory medicine fields. Built large-scale fully automatic assembly lines and small POCT product groups which focus on tumors, digestion and metabolism, cardiovascular and cerebrovascular diseases, reproduction, central nervous system, and infection.

In the future, Fosun Diagnostics will continue to build an open R&D ecological platform, promote the development and landing of innovative technologies and products, focus on the IVD industry, and strive to become the world’s leading scientific innovator in the overall solution of medical diagnosis.
**FUTURE DIAGNOSTICS**

We, at Future Diagnostics, are laboratory professionals creating in-vitro diagnostic tests and products. A service provider and a development partner to biotech companies in the global IVD medical device market. We invent, create and validate the best possible IVD tests for our clients. Whether you need highly specialized knowledge or manpower to bring your concept to market, we are your trusted independent partner for the development of many different types of IVD immunoassays, with different technologies, either manually or automated; e.g. colorimetric (ELISA, EIA), Fluorescent, Chemiluminescent (CLIA), Multiplex Micro-Array, Point of Care or Turbidimetric. Our team of experienced professionals has been doing this for clients around the world for 25 years. This is done with dedication, integrity, transparency, and flexibility.

Future Diagnostics Solutions
Nieuweweg 279
6603 BN Wijchen
The Netherlands
info@future-diagnostics.com
www.future-diagnostics.com

---

**GENETIC ANALYSIS AS**

Genetic Analysis AS (GA) is a Norwegian diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of up to 300 bacteria in one reaction. The test results are generated by the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. The GA-map® Dysbiosis Test Lx is the first validated and CE-marked routine diagnostic platform for gut microbiome, as an easy entry for the clinical laboratory to perform microbiome analysis. GA's vision is to make the microbiota widely accessible to human healthcare by become the leading company for standardized gut microbiota testing worldwide. GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology.

www.genetic-analysis.com

---

**GENTIAN**

Gentian is a Norwegian diagnostics company that develops and supplies assays for clinically relevant biomarkers available on high-throughput clinical chemistry platforms, utilising Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology. Our current portfolio and future pipeline of diagnostic reagents span diverse areas like kidney disease, cardiac disease, inflammation, infection and veterinary medicine.

In combining 20+ years of industry experience with unique and proprietary technologies Gentian's goal is to increase diagnostic efficiency and decrease the cost of diagnostic testing. Current portfolio includes cystatin C, GCAL® plasma and serum calprotectin, canine CRP and faecal calprotectin and pancreatic assays, SARS-CoV-2 Total Antibody (2021) and NT-proBNP (2022). We have more assays under development and plan to bring a new assay to the market every year.

Gentian products are designed for use in open channels on all major clinical chemistry analysers already available in your laboratory. We supply our reagents to both clinical laboratories and instruments providers.

Gentian AS
PO Box 733 - 1509 Moss - Norway
marketing@gentian.com - www.gentian.com

---

**GMT SCIENCE**

GMT Science specializes in the bioinformatic analysis of the gut microbiome. We enable laboratory medicine professionals to enrich their fecal analysis offer, in particular for the clinical diagnosis and management of gastrointestinal disorders.

GMT Science
partnering@gmt.bio
27-33 Rue du Colonel Pierre Avia
75015 Paris

---

**GREINER BIO-ONE**

Greiner Bio-One specializes in the development, production and distribution of high-quality plastic laboratory products. The company is a technology partner for hospitals, laboratories, universities, research institutes, and the diagnostic, pharmaceutical and biotechnology industries. Greiner Bio-One is split into three divisions - Prenanalytics, BioScience and Sterilization. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides individual solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors. In 2020, Greiner Bio-One International GmbH generated a turnover of 693 million euros and had 2,375 employees, 28 subsidiaries and numerous distribution partners in over 100 countries. Greiner Bio-One is part of Greiner AG, which is based in Kremsmünster (Austria).

Greiner Bio-One GmbH
Bad Haller Strasse 32
4550 Kremsmuenster, Austria
office.atgbo@gbo.com
+43 7583 6791-0

---

**HEMCHECK SWEDEN**

Hemcheck Sweden AB is a publicly listed medtech company manufacturing and commercializing a patented, CE-marked concept, HELGE™, that detects hemolysis in venous and arterial blood samples in vacuum tubes and blood gas syringes during blood collection at the point of care. Hemolysis distorts analytical values and increases lead times, which might result in delayed, missing or wrong diagnosis and treatment for the patient. The vision of Hemcheck is to create hemolysis free blood sampling to ensure safe and effective healthcare delivery.

The v-Test for vacuum tubes enables hemolysis detection and direct sample retake in connection with blood collection and aims to improve the flows of samples and patients, reduce waiting times, turnaround times and patient length of stay, decrease staff workload, increase patient safety and save healthcare costs.

Blood gas analysis is currently done without the possibility of detecting hemolysis. The new bgs-Test for blood gas syringes has multiple functions such as hemolysis test with integrated ventilator for air bubbles and an airtight
cap for improved adaptation to the current workflows. The bgs-Test enables hemolysis detection either in connection with blood sampling or blood gas analysis and aims to contribute to more informed, reliable and timely clinical decisions and thereby improved patient safety.

Hemcheck Sweden AB
Universitetsgatan 2
SE-651 88 Karlstad - Sweden
+46 708 74 25 22
peter.andersson@hemcheck.com
www.hemcheck.com

HYCOR BIOMEDICAL

At HYCOR, we believe that people with an allergy improve their quality of life when they know exactly what is causing their symptoms. Defining the underlying allergens is key! With over 40 years of experience, HYCOR Biomedical is a global manufacturer and marketer of in vitro diagnostic products.

Since its founding in 1981, HYCOR has supported clinical laboratories, hospitals and doctors’ offices worldwide with allergy and autoimmune instrumentation and reagents. Among its products, HYCOR markets the HYTEC® and the NOVEOS Immunoassay System. Each has received CE Mark for the European Union and FDA clearance in the United States. The company is focused on delivering innovative technology products and comprehensive services that provide the highest value to physicians and laboratories.

HYCOR Biomedical
7272 Chapman Avenue - Garden Grove
California 92841, USA
+1 714 933 3000
CustomerServices-US@hycorbiomedical.com
HYCOR Europe B.V. Mercuriusplein 19b,
2132 HA Hoofddorp Netherlands
+31 (0)20 899 4280
CSEurope@hycorbiomedical.com

IMMUNDIAGNOSTIK

Immundiagnostik AG (www.immundiagnostik.com), founded in 1986 by Dr. Franz Paul Armbuster (CEO), is specialized on the development, production, and worldwide distribution of innovative parameters and detection methods for laboratory diagnostics and medical research. The main focus is the development of immunological tests (ELISA), of HPLC and molecular biology methods, and of new applications for mass spectrometry (LC-MS/MS). Immundiagnostik concentrates on the development and production of laboratory diagnostics for the identification of disease risks, for differential diagnosis, and for therapeutic drug monitoring. The company holds a particularly strong portfolio in markers of oxidative stress/anti-aging, gastroenterology and nutrition, skeletal system, and cardio-reno-vascular system. Immundiagnostik owns more than 35 patents in Europe, the US, Japan, Canada, and Australia, is certified according to DIN EN ISO 13485 and fulfills the requirements of the German Medical Device Regulation and the EU IVD Regulations (98/79 EG).

Immundiagnostik AG
Stubenwald-Allee 8a - DE-64625 Bensheim
Tel.: +49 6251 70 190 0
Fax: +49 6251 70 190 368
E-Mail: info@immundiagnostik.com
Website: www.immundiagnostik.com

INPECO

Inpeco is the global leader in Total Laboratory Automation. Our pioneering solutions combine open automation with full sample traceability to deliver secure test results and increased productivity to laboratories around the world. Inpeco’s solutions guarantee operator safety by removing any contact with biological samples and ensure the total diagnostic testing is error-free - from blood drawing to results availability.

Discover our product videos on the YouTube channel of the Inpeco website!

Inpeco SA
Via Torraccia 26
6883 Novazzano
Switzerland

Riccardo Melis
Riccardo.melis@inpeco.com
+390117548204

IVD GROUP

We are a young, perspective company dedicated to becoming a market leader in implementation of the latest technologies in laboratory medicine.

We are a proud manufacturer of a Unique smartwatch SAMPLIFY for preanalytical phase management and exact sampling time tracking. SAMPLIFY is specially designed for medical nurses responsible for sample collection procedures with an integrated smart assistant based on EFLM recommendations for good practices in phlebotomy.

Halo is another IVD product line with a range of MDx reagents, disposables and a real-time PCR cycler SUN96.

We are a family company and believe that our clients should feel as a part of a family. We build our reputation on reliability, business ethics, highly qualified personnel and excellent quality of work.

IVD Group Sp. z o.o.
Address: Poland, 00-337 Warszawa ul. Bartoszewicza 3-24
Email: info@ivdgroup.eu
Contact number: +375 29 116 14 91

LUMIRADX

LumiraDx is a next-generation point of care diagnostics company that is transforming community-based healthcare. Founded in 2014, the company manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. LumiraDx’s diagnostic testing solutions are being deployed by governments and leading healthcare institutions across laboratories, urgent care, physician offices, pharmacy, schools, and workplaces to screen, diagnose and monitor wellness as well as disease. The company has on the market and in development 30+ tests covering infectious diseases, cardiovascular disease, diabetes and coagulation disorders, all on the LumiraDx Platform. In addition, the company has a comprehensive portfolio of fast, accurate and cost-efficient COVID-19 testing solutions from the lab to point of need.

LumiraDx is based in the UK with more than 1500 employees worldwide.

For more information please visit www.LumiraDx.com

Events@LumiraDx.com
LumiraDx Limited
3 More London Riverside
London, SE1 2AQ
United Kingdom
**MEDCAPTAIN MEDICAL TECHNOLOGY**

Medcaptain Medical Technology Co., Ltd. is dedicated to providing high-quality medical devices and services. As an integrated perioperative solutions provider, our services cover Medication Delivery, Airway Management, In-Vitro Diagnostics, and DVT Prevention. As a state-level hi-tech enterprise, Medcaptain has been granted over 200 patents and the copyright for 15 software applications. Medcaptain has set up offices in central cities of China and other countries like the Netherlands, Turkey, India, Thailand and Colombia. Our products are widely used in top level university teaching hospitals in China, as well as the medical institutions in over 100 countries.

**NIHON KOHDEN**

Since Nihon Kohden’s foundation in 1951, our mission is “Improving Healthcare with Advanced Technology”. As a leading manufacturer of electronic medical equipment, we provide solutions for the clinical practice all around the world. At Nihon Kohden, we respond to emerging needs by providing the latest technology and clinical solutions for earlier diagnosis and better outcomes.

https://eu.nihonkohden.com

**NOVA BIOMEDICAL**

Nova is a world leader in point of care and critical care in vitro diagnostics. Our products include:
- Stat Profile Prime Plus® blood gas critical care analyser featuring maintenance-free sensors and a 22-test menu including tests for iMg, Urea, Creatinine, ePV and Co-oximetry.
- StatStrip® Glucose/Ketone provides lab-accurate measurements while eliminating interferences from haematocrit, maltose, oxygen, and other substances.
- StatStrip® Lactate/Hb & Hct offers rapid screening and monitoring of sepsis or use as an alternative to fetal scalp pH testing in the delivery suite; the Hb & Hct strip provides a rapid anaemia assessment.
- StatSensor® Creatinine measures capillary whole blood creatinine and calculated eGFR for rapid renal function prior to using contrast media in radiology.
- Allegro®, a compact analyser measuring HbA1c, Lipids, Glucose, Creatinine, CRP and PT/INR from capillary whole blood, plus Urine Albumin and Creatinine; with all tests using disposable cartridges and test strips.

Nova Biomedical
200 Prospect Street
Waltham, Massachusetts 02454 USA
Tel. 781-894-0800 - Fax. 781-894-5915
Email. info@novabio.com
Web site. www.novabiomedical.com

**NZYTECH**

NZYTECH manufactures and supplies high-quality enzymes, mixes and kits for molecular research and diagnostics in Life Science Research and Clinical Diagnostics, including custom and OEM solutions. From qPCR & One-step RT-qPCR Master Mixes, to Reverse Transcriptases, to Ribonuclease Inhibitors and Polymerases. Additionally, our Clinical Diagnostics solutions have a range of CE-IVD certified product
ISO 135485 - ISO 9001 - CE-IVD
Raw Materials: qPCR & One-step RT-qPCR Master Mixes; Reverse Transcriptases; Ribonuclease Inhibitors; Polymerases
Molecular Diagnostics: SARS-CoV-2 (CE-IVD); Respiratory Viruses (CE-IVD); RT-qPCR Kits (>200 kits RUO); Mag Beads vRNA/vDNA (CE-IVD)
NZYTECH
Estrada do Paco do Lumiar Campus do Lumiar - Edif. E - 1º
1649-038 Lisboa, Portugal
info@nzytech.com

**PANASONIC INDUSTRY EUROPE**

Panasonic Industry Europe GmbH is part of the global Panasonic Group and provides products and services for the automotive and industrial sectors in Europe. As a partner for the industry, Panasonic researches, develops, manufactures, and delivers technologies that support the slogan “A Better Life, A Better World”. The company’s portfolio ranges from key electronic components, devices, and modules to complete solutions and production equipment for manufacturing lines in a variety of industries. Panasonic Industry Europe is part of the global Panasonic Industrial Solutions company. More about Panasonic Industry Europe:
http://industry.panasonic.eu

**PHC EUROPE**

As part of the PHC Group we are one of the world’s most important producers and suppliers of high-quality laboratory equipment, we contribute to advancing life science. With two business fields within our division – biomedical and diagnostics - we serve a broad and growing spectrum of life science facilities. Our products are used by researchers and other professionals in pharmaceutical, biotechnology and healthcare fields. They are also important in industrial and transport markets.

**QUIDEL CORPORATION**

Quidel Corporation is a leading manufacturer of diagnostic solutions at the point of care, delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names, Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive
product portfolio includes tests for a wide range of infectious diseases, cardiac and autoimmune biomarkers, as well as a host of products to detect COVID-19. With products made in America, Quidel's mission is to provide patients with immediate and frequent access to highly accurate, affordable testing for the good of our families, our communities and the world.

Quidel Ireland Ltd.
2nd Floor, Merchants Square Merchants Road
Galway, Ireland H91 ETN2
www.quidel.com

REETOOL BIOTECHNOLOGY
Reetoo Biotechnology Co., Ltd.
Add: F406, Huafeng Robot Industrial Park, Hangcheng Avenue, Bao'an District, Shenzhen, China
Contact: +86-755-8966760 Email: market@reetoo.com.cn
web: www.reetoo.com.cn

SANSSURE BIOTECH INC.
Sanssure Biotech Inc. now a listed company in China established in 2008, is an integrated solutions manufacturer and provider with independent innovation of molecular diagnostics and gene technology, has over 10-year experience specialized in diagnostic reagents, nucleic acid diagnostic instruments, complete lab solutions and lab chain services. Sanssure solutions for molecular diagnosis are compatible with majority of PCR detection instruments and lab environments based on unique technical platforms: global leading magnetic beads extraction system “one of the simplest and fastest one-step DNA/RNA lysis systems” automated nucleic acid extraction system POCT devices and real-time PCR instruments Over 40% of its employees work for R&D and technical service departments, over one hundred of products with global registrations, including infectious diseases cancer, maternal and child health, blood screening, emerging infectious diseases prevention and control, chronic disease management, etc.

SARSTEDT
SARSTEDT develops & produces instruments & consumables for medicine & science and is one of the leading suppliers in this field.
Especially for research in life sciences, SARSTEDT has developed a comprehensive range of consumables for sample collection & storage, liquid handling, molecular biology as well as products for cell cultivation. The consumables used worldwide include tools like pipette tips, screw cap micro tubes, reaction & centrifuge tubes, PCR tubes & flasks, plates & dishes with tissue culture (TC) treated growth surfaces.
The superior biological purity of SARSTEDT’s Biosphere® plus products is guaranteed by a certified production process that complies with the strictest purity requirements so that customers can be sure to achieve utmost impact, comparability and reproducibility in their in-vitro work.
The comprehensive range of high quality products, attendance to customers and excellent service make SARSTEDT a partner in medicine & science worldwide.
SARSTEDT AG & Co. KG
Sarstedtstraße 1 - D-51588 Nümbrecht
Tel: +49 (0)2293 305-0 - Fax: +49 (0)2293 305-2470
info@sarstedt.com

SHIMADZU
Shimadzu is one of the worldwide leading manufacturers of analytical instrumentation. Its equipment and systems are used as essential tools in all areas of clinical research. Since more than 140 years, Shimadzu is at the service of science ensuring precise and reliable analyses. Among the leaders in Mass spectrometry technologies, Shimadzu has been paving the way for automation of sample preparation prior to LC-MS/MS analysis for the clinical field. In addition, Shimadzu is offering a full range of solutions including instruments, reagents, standards as well as sampling technologies. Take the opportunity to discover the LCMS portfolio (IVD and RUO), the full automation with CLAM-2030 and our clinical reagent kits during Euromedlab 2021!
Shimadzu Europa GmbH
Albert-Hahn-Straße 6-10 - 47269 Duisburg - Germany
Phone: +49 (0)203-7687-0 - E-mail: info@shimadzu.eu
Website: www.shimadzu.eu

T&O LABSYSTEMS
T&O LabSystems is an innovative family business established in 2009. We contribute significantly to the safe and efficient logistics of blood and urine sample tubes - from sample collection to analysis. With more than 450 installed systems worldwide as well as numerous cooperations in the OEM sector, T&O LabSystems has established itself as a reliable partner for medical laboratories and companies. Our 4th generation ATRAS is a cost-effective solution for the registration and sorting of samples into bulk bins, racks and centrifuge buckets. The modular concept allows fully customized solutions for individual workflows. The intelligent transport system InTrac ensures barrier-free and cost-effective distribution of closed samples throughout the laboratory. Our TriCollect solution enables safe sample transport from the laboratory
according to UN 3373 while completely avoiding plastic waste. ATRAS, InTrac and TriCollect integrate and work well together, thus adding value through synergy. Experience our products and their synergy live at our booth.

T&O LabSystems GmbH & Co. KG
Leibnizstraße 7 - 24568 Kaltenkirchen - Germany
https://to-labsystems.com - info@to-labsystems.com
+49 (0) 4191 99 13 88 3

TASCOM
TASCOM stands for Total Analysis System Company. Since founded in Koran in 2013, TASCOM Co., Ltd has successfully developed SimplexTASTM enables healthcare professionals to diagnose various diseases from patient more quickly and easily. More importantly it provides lab-quality results by adopting the same principles and mechanism as laboratory clinical analyzers. Our mission is to enhance human wellness and improve efficiency and values in healthcare by providing accurate and user-friendly products. Through our continuous innovation and core technologies, we will keep providing best quality diagnostic products and become a global leader in in-vitro diagnostic field.

TECHNOPATH CLINICAL DIAGNOSTICS
Technopath Clinical Diagnostics is a global leader in the development, manufacturing and delivery of high-quality independent quality controls and QC data management software for the IVD industry. Laboratories that use Multichem® consolidated independent quality controls experience simplified inventory, reduced costs and improved efficiencies. Technopath's enhanced offering of barcode consolidated QC, combined with IAMQC® informative software, offer unique work-flow automation, whereby controls can be stored on-board and/or simply presented to the instrument for use. Technopath is valued as a single, trusted source that helps laboratories achieve their QC goals with a broad portfolio of QC products and comprehensive range of informatics solutions and support services.

Technopath Clinical Diagnostics,
Technopath Life Sciences Park, Fort Henry, Ballina, Co. Tipperary, V94 FF1P, Ireland.
www.technopathcd.com - info@technopathcd.com
Tel: +353 61 525700.

VIRAMED® BIOTECH
Based on more than 38 years of experience in European and American markets Viramed® develops, produces and sells In-Vitro-Diagnostic test kits. Through proprietary research and development the ViraChip® microarray product line is continuously expanding. Viramed® focuses on the serological detection of autoantibodies as well as antibodies against infectious disease parameters like Borrelia, Yersinia, Treponema, Helicobacter, Bordetella, SARS-CoV-2, EBV, CMV, Hepatitis E Virus, Parvovirus B19, Zika Virus, Dengue Virus, Chikungunya Virus and Toxoplasma.

Software solutions, device design and manufacturing provide full automation for the ViraChip® technology in the diagnostic laboratory.

WATTERS CORPORATION
Waters Corporation, (NYSE:WAT), creates business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation in the areas of liquid chromatography and mass spectrometry, two vital enabling technologies for today’s state-of-the-art analytical laboratories. Waters instruments and software enable significant advancements in such areas as healthcare delivery, clinical research, forensic toxicology, sports medicine, drug discovery and development worldwide. Bringing keen understanding and deep experience to those responsible for laboratory infrastructure and performance, Waters helps its customers meet client expectations and satisfy delivery timetables, make profound discoveries, manage laboratory operations, and meet current Good Laboratory Practice (GLP) requirements and comply with federal and international regulatory guidelines.

Pioneering a connected portfolio of liquid chromatography and mass spectrometry products, laboratory consumables, laboratory informatics, and post-sale support services, Waters' technology breakthroughs and laboratory solutions provide an enduring platform for customer success. Visit www.waters.com for more information.

ZYBIO
Zybio Inc., est. in 2008, is a high-tech enterprise specialized in IVD equipment and reagents’ R&D, manufacture, sales and technical services, headquartered in Chongqing Municipality, China. Zybio has over 3,200 employees worldwide, including 1,000+ R&D personnel. Around 15% of annual revenue is continuously invested to R&D as well as innovative attempts.

To attract talents, Zybio established 7 R&D centers in different top-tier cities all across China. By far, Zybio portfolio consists of clinical chemistry, chemiluminescence immunoassay, molecular biology, hematology, microbiology, pathology and POCT.

Zybio global business covers 110+ countries, benefited 13,000+ end users (until September, 2021). Zybio strives to reshape IVD products by bettering quality with advanced and efficient technique.

ZYMO
From its birthplace in a small garage in Orange, California, to the industry leader it is today, Zymo Research has been led by the vision to have a positive impact in the biomedical field and to contribute to the greater good of humanity. That vision touches every aspect of Zymo Research and has guided the company’s growth, culture and creation of the most innovative and valuable biomedical tools and services since 1994.

Now, Zymo Research is a globally established biotechnology company and industry leader in the fields of epigenetics, microbiomics and the emerging Next-Gen Sequencing space. While the company provides some of the most technologically advanced and reliable products in the industry, everything is driven by the fundamental belief that “the beauty of science is to make things simple.”
Point of care testing within the Emergency Department has enabled rapid diagnosis and treatment of patients. However, even devices that are well maintained and managed can, in some circumstances provide results that are erroneous. This workshop, with the use of data from three institutions will provide insights into how POCT errors can impact patient care and hospital resources, presented by:

Professor Peter Luppa
Head of the Core Clinical Chemistry Laboratory at the Institute for Clinical Chemistry and Pathobiochemistry in Munich, Germany

Dr Andrei Tintu
Point of Care Director and Chief Laboratory Information Officer at Erasmus MC, University Medical Center in Rotterdam, the Netherlands

Dr Antonio Buño Soto
Point of Care Director and Head of Clinical Analysis Services at the La Paz University Hospital in Madrid, Spain

Let’s have a conversation!
Meet our BD team of experts at Booth #75 to learn more about our innovative solutions and professional services.
EXHIBITION MAP

CATERING AREA

Poster Area

Entrance to the Exhibition Area
<table>
<thead>
<tr>
<th>COMPANY</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. MENARINI DIAGNOSTICS</td>
<td>10</td>
</tr>
<tr>
<td>ABBOTT</td>
<td>43</td>
</tr>
<tr>
<td>ARK DIAGNOSTICS</td>
<td>182</td>
</tr>
<tr>
<td>ASP LAB AUTOMATION</td>
<td>107</td>
</tr>
<tr>
<td>BD</td>
<td>75</td>
</tr>
<tr>
<td>BIO-RAD LABORATORIES</td>
<td>168</td>
</tr>
<tr>
<td>BÜHLMANN</td>
<td>29</td>
</tr>
<tr>
<td>BYG4LAB</td>
<td>108</td>
</tr>
<tr>
<td>COLLEGE OF AMERICAN PATHOLOGISTS</td>
<td>219</td>
</tr>
<tr>
<td>COMED</td>
<td>215</td>
</tr>
<tr>
<td>DIAGAM</td>
<td>119</td>
</tr>
<tr>
<td>DIASORIN</td>
<td>183</td>
</tr>
<tr>
<td>DIASOURCE</td>
<td>228</td>
</tr>
<tr>
<td>DIASYS</td>
<td>226</td>
</tr>
<tr>
<td>DIESSE</td>
<td>216</td>
</tr>
<tr>
<td>DIRUI</td>
<td>109</td>
</tr>
<tr>
<td>EDAN INSTRUMENTS</td>
<td>202</td>
</tr>
<tr>
<td>ELITECH GROUP</td>
<td>227</td>
</tr>
<tr>
<td>EXIAS MEDICAL</td>
<td>188</td>
</tr>
<tr>
<td>FOSUN DIAGNOSTICS</td>
<td>173</td>
</tr>
<tr>
<td>FUTURE DIAGNOSTICS</td>
<td>203</td>
</tr>
<tr>
<td>GENETIC ANALYSIS</td>
<td>169</td>
</tr>
<tr>
<td>GENTIAN</td>
<td>201</td>
</tr>
<tr>
<td>GMT SCIENCE</td>
<td>181</td>
</tr>
<tr>
<td>GREINER BIO-ONE</td>
<td>221</td>
</tr>
<tr>
<td>HEMCHECK SWEDEN</td>
<td>189</td>
</tr>
<tr>
<td>HORIBA MEDICAL</td>
<td>28</td>
</tr>
<tr>
<td>HYCOR BIOMEDICAL</td>
<td>190</td>
</tr>
<tr>
<td>IMMUNDIAGNOSTIK</td>
<td>220</td>
</tr>
<tr>
<td>INPECO</td>
<td>95</td>
</tr>
<tr>
<td>IVD GROUP</td>
<td>225</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>BOOTH</th>
</tr>
</thead>
<tbody>
<tr>
<td>LUMIRADX</td>
<td>250</td>
</tr>
<tr>
<td>MEDCAPTAIN MEDICAL TECHNOLOGY</td>
<td>265</td>
</tr>
<tr>
<td>MINDRAY</td>
<td>111</td>
</tr>
<tr>
<td>NIHON KOHDEN</td>
<td>120</td>
</tr>
<tr>
<td>NOVA BIOMEDICAL</td>
<td>179</td>
</tr>
<tr>
<td>NZYTECH</td>
<td>171</td>
</tr>
<tr>
<td>PANASONIC INDUSTRY EUROPE</td>
<td>94</td>
</tr>
<tr>
<td>PHC EUROPE</td>
<td>248</td>
</tr>
<tr>
<td>QUIDEL</td>
<td>224</td>
</tr>
<tr>
<td>RANDOX</td>
<td>7</td>
</tr>
<tr>
<td>REETO BIOTECHNOLOGY</td>
<td>223</td>
</tr>
<tr>
<td>ROCHE</td>
<td>125</td>
</tr>
<tr>
<td>SANSURE BIOTECH</td>
<td>230</td>
</tr>
<tr>
<td>SARSTEDT</td>
<td>165</td>
</tr>
<tr>
<td>SEBIA</td>
<td>121</td>
</tr>
<tr>
<td>SENTINEL CH</td>
<td>205</td>
</tr>
<tr>
<td>SHIMADZU</td>
<td>187</td>
</tr>
<tr>
<td>SIEMENS HEALTHINEERS</td>
<td>83</td>
</tr>
<tr>
<td>SNIBE</td>
<td>193</td>
</tr>
<tr>
<td>STAGO</td>
<td>261</td>
</tr>
<tr>
<td>SYSMEX</td>
<td>207</td>
</tr>
<tr>
<td>T&amp;O LABSYSTEMS</td>
<td>191</td>
</tr>
<tr>
<td>TASCOM</td>
<td>204</td>
</tr>
<tr>
<td>TECHNO PATH CLINICAL DIAGNOSTICS</td>
<td>115</td>
</tr>
<tr>
<td>THE BINDING SITE</td>
<td>15</td>
</tr>
<tr>
<td>THERMO FISHER SCIENTIFIC</td>
<td>247</td>
</tr>
<tr>
<td>VIRAMED BIOTECH</td>
<td>93</td>
</tr>
<tr>
<td>WERFEN</td>
<td>175</td>
</tr>
<tr>
<td>ZYBIO</td>
<td>217</td>
</tr>
<tr>
<td>ZYMO RESEARCH EUROPE</td>
<td>27</td>
</tr>
<tr>
<td>VISION'S TECHNICAL OFFICE</td>
<td>251</td>
</tr>
<tr>
<td>PLATINUM SPONSORS</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>Abbott</td>
<td></td>
</tr>
<tr>
<td>Roche</td>
<td></td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GOLD SPONSORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randox</td>
</tr>
<tr>
<td>Snibe</td>
</tr>
<tr>
<td>Sysmex</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SILVER SPONSORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mindray</td>
</tr>
<tr>
<td>Ortho</td>
</tr>
<tr>
<td>Sebia</td>
</tr>
<tr>
<td>Binding Site</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>BRONZE SPONSORS</th>
</tr>
</thead>
<tbody>
<tr>
<td>BD</td>
</tr>
<tr>
<td>Diasorin</td>
</tr>
<tr>
<td>ELITechGroup</td>
</tr>
<tr>
<td>Thermo Fisher</td>
</tr>
<tr>
<td>Stago</td>
</tr>
<tr>
<td>Werfen</td>
</tr>
</tbody>
</table>
ADDRESSING COMPLEX CHALLENGES WITH INDIVIDUAL SOLUTIONS IS NO LONGER ENOUGH

ABBOTT END TO END SOLUTIONS
When combined, these solutions unlock synergistic value, helping your laboratory achieve and sustain excellence

RESOURCESFUL ADVOCATES  HARMONIZED SYSTEMS  INTELLIGENT INSIGHTS

Visit Abbott Diagnostics at EuroMedLab 2021 to see how our End to End solutions can help you drive efficiencies in your laboratory to achieve measurably better outcomes.

CORELABORATORY.ABBOTT
3rd EFLM STRATEGIC CONFERENCE
SMART AND GREEN LABORATORIES
How to implement IVDR, emerging technologies and sustainable practices in medical laboratories?

MAY 2022
25 26 27

VIRTUAL CONFERENCE

www.eflm-strategic-conference.eu

ORGANISING SECRETARIAT
MZ Events s.r.l.
Via Carlo Farinai 81 - 20159 Milano (Italy)
Phone: +39 02 66802323 Fax: +39 02 6686699
E-mail: patrizia.sirtori@MZevents.it

Platinum Sponsor
Gold Sponsor
Bronze Sponsor
Bronze Sponsor
Optilite®

Optimised and proven special protein analysis

Optilite brings you a new level of efficiency, workflow optimisation and confidence in results

⚡️ Enhance your efficiency
   Save time and reduce your costs with this easy-to-use, intelligent system

⚡️ Optimise your workflow
   Streamline your workload for smart resource management and optimal productivity

⚡️ Increase your confidence
   Excellent reliability ensures you will always deliver the best possible protein testing service

Find us at Booth 18 for a demonstration

Contact Us
www.bindingsite.com
info@bindingsite.com
+44 (0) 121 456 9500